タイ国薬用植物Mitragyna speciosa成分7-hydroxymitragynineのオピオイド鎮痛作用に関する薬理学的研究 by 松本, 健次郎 & マツモト, ケンジロウ
  
 
 
Pharmacological Studies on 7-Hydroxymitragynine, 
 Isolated from the Thai Herbal Medicine Mitragyna speciosa: 
Discovery of an Orally Active Opioid Analgesic 
 
 
 
 
 
 
 
 
 
 
Kenjiro Matsumoto 
 
2006
Contents 
 
General Remarks                1 
 
Part Ι. Exploration of compounds acting on opioid receptors in components of  
Mitragyna speciosa and its related synthetic alkaloids 
 1. Introduction              8 
 2. Materials and methods                          8 
 3. Results              12 
 4. Discussion              17 
 
Part ΙΙ. Elucidation of opioid effect of 7-hydroxymitragynine and 9-hydroxycorynanthidine 
by in vitro assays 
 1. Introduction             20 
 2. Materials and methods           20 
 3. Results              25 
 4. Discussion              30 
 
Part ΙΙΙ. Antinociceptive and side effects of 7-hydroxymitragynine in mice: Discovery of  
a potent and orally active opioid analgesic 
 1. Introduction             35 
 2. Materials and methods           36 
 3. Results              40 
 4. Discussion              50 
 
Part IV. Effects of mitragynine on isolated tissues 
 1. Introduction             56 
 2. Materials and methods            56 
 3. Results               61 
 4. Discussion              67 
 
Concluding Remarks              70 
 
References               72 
 
List of publications              79 
 
Acknowledgements              82 
            
General Remarks 
 
Substances derived from natural products have been utilized since the beginning of time for 
various medical purposes including the treatment of pain. Opium, for example, has been mentioned in 
the earliest historical records, some 7000 years ago. In fact, research in the area of pain management 
and drug addiction originally focused on natural products exclusively. Prototypical examples of such 
natural products are the opium poppy (Papaver somniferum). Morphine, an alkaloid component of the 
opium poppy, is the most widely used compound among narcotic analgesics and remains the gold 
standard. Recently, analogs have been produced from natural substances, and completely synthetic 
compounds based on natural pharmacophores have been introduced to the market. However, the 
research and medical fields still struggle with the undesirable side-effects of these analgesic 
substances (McCurdy and Scully 2005). 
Our research group has studied uniquely structured, nitrogen-containing compounds isolated 
from the traditional Thai herb Mitragyna speciosa. This herb has long been used in tropical areas for 
its opium- and coca-like effects (Burkill, 1935). It has been used also as a substitute for opium and to 
wean addicts off morphine (Grewal, 1932; Suwanlert, 1975). We have been investigating the 
pharmacological properties of this herb, individual components of its extracts, and structurally related 
compounds since the 1980s. We compared the antinociceptive effects of Mitragyna speciosa and 
mitragynine, the major alkaloid of this herb, in in vivo experiments, and found that the antinociceptive 
effect of mitragynine was less potent than that of the crude extract of Mitragyna speciosa (Watanabe 
et al., 1992, 1999). This finding means that one or more minor constituents of Mitragyna speciosa 
may have a very potent antinociceptive effect. We have investigated mitragynine-related compounds 
that express interesting opioid activities: an oxidative derivative of mitragynine, mitragynine 
pseudoindoxyl, was found to exhibit potent opioid agonistic activity in vitro and antinociceptive 
activity in vivo (Yamamoto et al., 1999; Takayama et al., 2002). These findings prompted us to 
embark on the development of novel compounds based on the mitragynine skeleton, which is quite 
different from the skeleton of morphine.  
In the present study attempting to find a new analgesic from the Thai herbal medicine, I surveyed 
the opioid effects of the other constituents of Mitragyna speciosa and synthetic derivatives of 
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mitragynine by the Magnus method in isolated smooth muscle preparations. Among them, I found a 
novel alkaloid, 7-hydroxymitragynine, a minor constituent of Mitragyna speciosa, and investigated 
the involvement of opioid receptor subtypes by in vitro assays. Furthermore, I investigated the 
antinociceptive and side effects of 7-hydroxymitragynine in vivo and compared them to the effects of 
morphine to evaluate the clinical utility of 7-hydroxymitragynine. 
 
 
1. Historical overview of Mitragyna speciosa  
 
     Mitragyna speciosa Korth has been used for many years in Thailand, Malaysia, Borneo, the 
Philippines, and New Guinea; the Thai and Malay natives use it as a substitute for opium. It is called 
“kratom” by the natives of Thailand and “biak-biak” in Malaysia. Natives used the leaves of the plant 
in fresh or dried forms, and they also prepared syrup by evaporating a solution made from dried 
leaves. The leaves were chewed, or the syrup was drunk after dissolving it in hot water, or even 
smoked in a way similar to opium. Besides the use of leaves of Mitragyna speciosa as a substitute for 
opium, other uses are a cure for fever, treatment for diarrhea, and a cure for opioid withdrawal 
syndrome (Burkill, 1935). Furthermore, Suwanlert (1975) reported the use of Mitragyna speciosa as a 
stimulant in Thailand by market gardeners, peasants, and laborers to overcome the burden of hard 
work as well increasing work efficiency under a scoring sun. His study on Mitragyna speciosa users 
in Thailand describes the stimulant effect and strong desire to work induced by the plant as leading to 
its regular use, which progresses to addiction. In these addicts, symptoms such as anorexia, weight 
loss, stomach distention, insomnia, darkening of the skin, constipation, and withdrawal syndrome 
were reported (Grewal, 1932; Suwanlert, 1975). 
In contrast, there are reports that Mitragyna speciosa use causes much less aggressiveness and 
hostility than opium smoking, that is, the absence of adverse physical conditions and character 
changes (Jansen and Prast, 1988). Mitragyna speciosa has a psychostimulant effect like coca and a 
depressive effect like opium and cannabis, which seem to be contradictory. It is also reported that it is 
weaker than morphine, has a milder withdrawal syndrome compared to opioids, and is less harmful 
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than cocaine. Although the medical use of Mitragyna speciosa to treat opium addicts in Thailand has 
been documented (Jansen and Prast, 1988; Burkill and Haniff, 1930), its use has been prohibited by 
Thai law since 1943 because of its narcotic effects. However, this law is not effective because the tree 
of Mitragyna speciosa is indigenous to the country. The fact is that the herb is not under any control in 
many other countries and is readily available on the Internet for purchase by anyone (McCurdy and 
Scully 2005).  
 
 
 
 
 
 
 
Chewing the leaves of Mitragyna speciosa 
          Mitragyna speciosa (kratom) leaves 
 
 
2. Pharmacology of mitragynine and its metabolite 
 
Mitragynine (Figure 1) is the major alkaloid of Mitragyna speciosa, and for this reason 
mitragynine was assumed to be the major chemical responsible for the effects of this herb. Hooper 
(1907) was the first person to isolate mitragynine, and this was repeated by Field (1921). Its structure 
was first fully determined by Zacharias et al. (1964). In the 1960s, the Chelsea group in the U.K. 
reported the isolation of several indole alkaloids from the leaves of Mitragyna speciosa from Thailand 
(Beckett et al., 1965, 1966a, b). Almost ten years later, Shellard et al. (1974) isolated more than 
twenty kinds of Corynanthe-type alkaloids, including oxindole derivatives, in their investigation of 
the alkaloid constituents in various samples of Mitragyna speciosa from Thailand. They pointed out 
that the variation in the constituents among different batches of leaves may be an indication of the 
presence of geographical variants of the species within Thailand (Shellard, 1974).  
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The pharmacology of Mitragyna speciosa and mitragynine was first explored by K. S. Grewal at 
the University of Cambridge in 1932. He performed a series of experiments on animal tissues and a 
group of five male volunteers. He described mitragynine as having a central nervous system stimulant 
effect resembling that of cocaine. Macko et al. (1972) reported that mitragynine exhibited 
antinociceptive and antitussive actions in mice comparable those of codeine. Their findings were that, 
unlike opioid analgesics at equivalent doses, mitragynine did not possess the side effects common to 
opioids. Moreover, the absence of an antagonistic effect of nalorphine on mitragynine-induced 
antinociception led them postulate noninvolvement of the opioid system in the action of mitragynine.    
 We have studied the pharmacological effects of mitragynine on guinea-pig ileum, mouse vas 
deferens, radioligand binding, and the tail-flick test in mice, and found that mitragynine acts on opioid 
receptors and possesses antinociceptive effects (Watanabe et al., 1997; Yamamoto et al., 1999; 
Takayama et al., 2002). But the effect of mitragynine was less potent than that of morphine. Some 
pharmacological investigations of mitragynine have also revealed that it has an antinociceptive action 
through the supraspinal opioid receptors, and that its action is dominantly mediated by µ- and δ-opioid 
receptors in in vivo and in vitro studies (Matsumoto et al., 1996a, b; Tohda et al., 1997; 
Thongpradichote et al., 1998).  
Another alkaloid of interest is mitragynine pseudoindoxyl (Figure 1), which was at first isolated 
as a metabolite of mitragynine by microbial biotransformation. Macko et al. (1972) reported that oral 
administration of mitragynine was more effective than subcutaneous administration. This finding 
suggested that the antinociceptive effect of mitragynine exists predominantly in its derivatives. Our 
previous study demonstrated a potent opioid agonistic property of compound mitragynine 
pseudoindoxyl in in vitro experiments (Yamamoto et al., 1999). In guinea-pig ileum, mitragynine and 
mitragynine pseudoindoxyl inhibit the twitch contraction through opioid receptors. The effect of 
mitragynine pseudoindoxyl was 20 fold more potent than that of morphine. In mouse vas deferens, the 
effect of mitragynine pseudoindoxyl was 35 fold more potent than that of morphine. In spite of its 
potent opioid effect, mitragynine pseudoindoxyl induced only a weak antinociceptive effect in the 
mouse tail-flick test in comparison with morphine (Takayama et al., 2002). 
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Figure 1 Chemical structures of mitragynine and mitragynine pseudoindoxyl 
 
 
3. Opioid receptor and analgesics  
 
Opioid is the common name for all compounds that have the same mechanism of action as the 
constituents of opium. All opioids interact with the endogenous opioid receptor system, which 
presently includes four known receptor subtypes (Dhawan et al., 1996) that are designated µ, δ, κ, and 
ORL-1 (opioid receptor-like receptor 1). These receptors are widely distributed in the mammalian 
system and have been found in all vertebrates. Their density is relatively high in the brain and spinal 
cord, but they are also found in the gastrointestinal system and the cells of the immune system. 
Although all three major types of opioid receptors, µ, δ, and κ-opioid receptors, are able to 
mediate analgesia/antinociception, their individual binding profiles and other pharmacological 
activities clearly distinguish one from another. Highly selective ligands that allow for receptor-type 
labeling have become available, and are summarized in Table 1. Of the three major classes of opioid 
receptors the µ-opioid receptor has proven to be the major target of opioid analgesics. Morphine is the 
prototypical µ-opioid analgesic that serves as the standard drug against which all analgesics are 
compared in determining their relative analgesic potencies. It has been recommended as the drug of 
choice in the management of patients with chronic cancer pain by the World Health Organization 
Cancer Unit in its Cancer Pain Relief Program. 
However, morphine also has undesirable effects, such as tolerance, withdrawal symptoms, 
constipation, respiratory depression, nausea, and vomiting. The majority of clinically available opioid 
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analgesics are µ-agonists derived from chemical templates that relate to the natural opium alkaloids, 
with progressive simplification through the morphinans to the benzomorphans and the piperidines, to 
the phenylpropylamines, e.g., fentanyl, pethidine, and methadone (Corbett et al., 2006).  
The major goals of opioid research are to understand the underlying biology of the endogenous 
opioid systems, to discover new analgesic drugs devoid of the unwanted side effects associated with 
morphine, and to develop new therapies for the treatment of opioid addicts. To find the ideal opioid 
analgesic, thousands of analogues have been synthesized, but an ideal analgesic that has a powerful 
effect yet is free from undesirable side effects has not been found at this stage. 
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Table 1 Opioid receptor and ligand relationship 
Currently accepted name      µ      δ      κ     ORL1 
Currently IUPHAR name     OP3     OP1     OP2    OP4 
Endogeneous ligands      β-Endorphin     Enkephalins   Dynorphin    Nociceptin/Orphanin FQ 
   Endomorphin-1 
   Endomorphin-2 
Exogeneous agonists     DAMGO    DPDPE (δ1)    U69593 (κ1)  Nociceptin/OrphaninFQ  
Fentanyl     DSLET (δ2)   U50488 (κ1) 
Morphine      
Selective antagonists      β-FNA (µ1, µ2)   Naltrindole (δ1, δ2)  norBNI (κ1, κ2)   
CTOP (µ1, µ2)   DALCE (δ1)    
Cyprodime (µ1, µ2)  naltriben (δ2) 
Naloxonazine (µ1) 
Non selective antagonists      Naloxone    Naloxone     Naloxone  
Naltrexone    Naltrexone   Naltrexone 
Radioligands of choice      [3H]DAMGO    [3H]Naltrindole   [3H]U69593   [3H] Nociceptin/Orphanin FQ 
[3H]Naloxone    [3H]DPDPE     [3H]norBNI 
Abbreviations 
norBNI, nor-Binaltorphimine; CTOP, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Phe-Thr-NH2; DALCE, [D-Ala2,Leu5,Cys6]-Enkephalin;  
DAMGO, [D-Ala2,N-Me-Phe4,Gly-ol5]-Enkephalin; DPDPE: [D-Pen2,5]-Enkephalin; DSLET, [D-Ser2,Leu5,Thr6]-Enkephalin; Endomorphin 1, Tyr-Pro-Trp-Phe-NH2; 
Endomorphin 2, Tyr-Pro-Phe-Phe-NH2; β-FNA, β-Funaltrexamine; U69593, (+)-(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl)benzeneacetamide; 
U50488, 3,4-Dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide
  
Part Ι. Exploration of compounds acting on opioid receptors in components 
of Mitragyna speciosa and its related synthetic alkaloids 
 
1. Introduction 
 
Mitragyna speciosa (called kratom in Thailand) has been used in Thailand for its opium- and 
coca-like effects. Additionally, it has been used to treat diarrhea and to wean addicts off morphine 
(Jansen and Prast, 1988). This medicinal herb contains many indole alkaloids (Houghton et al., 1991; 
Takayama et al., 1999, 2000). Mitragynine (Figure 1) is a main constituent of the leaves of Mitragyna 
speciosa (Takayama et al., 2000). Recently, we found that mitragynine acts on µ-opioid receptors in 
guinea-pig ileum (Watanabe et al., 1997; Yamamoto et al, 1999). In addition, some pharmacological 
studies have also revealed that mitragynine has an antinociceptive action through the supraspinal µ- 
and δ-opioid receptors (Matsumoto et al., 1996a, b; Tohda et al., 1997; Thongpradichote et al., 1998). 
The antinociceptive effect of mitragynine, however, is less potent than that of the crude extract of this 
plant (Watanabe et al., 1999). That is, the opium-like effect of Mitragyna speciosa cannot be fully 
explained by that of mitragynine. This finding suggests that minor constituents of Mitragyna speciosa 
have a very potent antinociceptive effect. However, this plant has not so far been investigated 
systematically for isolation of opioid agonistic constituents. In the present chapter, we fractionated the 
crude extract of Mitragyna speciosa, and explored active constituents that have opioid agonistic 
activities using an in vitro guinea-pig ileal contraction test. Furthermore, we surveyed the opioid 
agonistic activities of semi-synthetic compounds derived from mitragynine in order to elucidate 
specific structure necessary for its pharmacophore binding on opioid receptors.  
 
 
2. Materials and methods  
 
Animals 
 
All experiments were performed in compliance with the “Guiding Principles for the Care and 
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Use of Laboratory Animals” approved by the Japanese Pharmacological Society. The number of 
animals used was kept to the minimum necessary for a meaningful interpretation of the data, and 
animal discomfort was kept to the minimum. Male albino guinea pigs (320–540 g, Takasugi Lab. 
Animals, Japan) were killed by CO2 inhalation. 
 
Isolation of guinea-pig ileum 
 
The guinea-pig ileum was dissected and placed in Krebs-Henseleit solution (mM): NaCl, 112.08; 
KCl, 5.90; CaCl2, 1.97; MgCl2, 1.18; NaH2PO4, 1.22; NaHCO3, 25.00 and glucose, 11.49. The ileum 
was placed under 1 g tension in a 5 ml organ bath containing the nutrient solution. The bath was 
maintained at 37ºC and continuously bubbled with a mixture of 95% O2 and 5% CO2. Tissues were 
stimulated by a platinum needle-ring (the ring was placed 20 mm above the base of a needle 5 mm in 
length) electrode. After 60 min equilibration in Krebs-Henseleit solution, the ileum was transmurally 
stimulated (Cox and Weinstock, 1966) with monophasic pulses (0.2 Hz and 0.1 ms duration) by a 
stimulator (SEN-7203, Nihon Kohden, Tokyo, Japan). Contractions were isotonically recorded by 
using a displacement transducer (NEC Type 45347, San-ei Instruments Ltd., Tokyo, Japan). The 
effects of drug treatments on the twitch contractions evoked by transmural stimulation elicited 
through the ring electrodes were examined. At the start of each experiment, the maximum response to 
acetylcholine (3 µM) in each tissue was obtained to check its stability. The mean amplitude of the 
electrically-stimulated contraction was about 30% of the maximal response to acetylcholine (3 µM). 
The electrically-induced twitch contraction was almost abolished by tetrodotoxin (1 µM) and atropine 
(0.1 µM), as described previously (Watanabe et al., 1997). Thus, the electrical stimulation induced 
cholinergic contraction in guinea-pig ileum (Brookes et al., 1991). The height of the twitch response 
to transmural stimulation was measured before and after the drug challenge. Contraction (%) is 
expressed as a percentage of the twitch response to the transmural stimulation before the drug 
challenge.  
 
Plant material 
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 The leaves of Mitragyna speciosa were collected on the campus of the Faculty of Pharmaceutical 
Sciences, Chulalongkorn University. The plant was identified by Dr. Nijsiri Ruangrungsi, Faculty of 
Pharmaceutical Sciences, Chulalongkorn University. A voucher sample (#1991Dec-MS) was 
deposited in the Herbarium of the Faculty of Pharmaceutical Sciences, Chulalongkorn University. 
 
Extraction and isolation 
 
Big, young leaves were powdered (165.5 g) and extracted five times with hot methanol. The 
solvent was concentrated under reduced pressure to give a crude extract (53.5 g), a part of which was 
dissolved in 10% aqueous acetic acid (AcOH). The insoluble material was removed by filtration 
through Celite to give the AcOH-insoluble fraction solution (AcOH-insoluble fraction, 50.3 g). The 
aqueous layer was basified with Na2CO3 at 0°C and extracted with chloroform (CHCl3). The organic 
layer was washed with water, dried over MgSO4, and then evaporated to give the crude base fraction 
(2.43 g). The aqueous layer was further extracted with n-Butanol (BuOH), which was concentrated 
under reduced pressure to yield the n-BuOH fraction (4.77 g). A part of the residual aqueous solution 
(10 ml) was lyophilized to give a hygroscopic solid (ca. 2 g), which was isolated with ethanol using a 
Soxhlet extractor in order to remove the inorganic materials. The ethanol extract was evaporated to 
give a residue containing the water-soluble organic materials (water-soluble fraction, 1.08 g).  
The crude base fraction (2.0 g), which exhibited an opioid agonistic effect on the guinea-pig 
ileum, was purified by SiO2 column chromatography (6 × 17 cm) using CHCl3/ethyl acetate (AcOEt) 
(9:1, 370 ml; fraction A), CHCl3/AcOEt (4:1, 240 ml; fraction B), CHCl3/AcOEt (1:1, 320 ml; 
fraction C), AcOEt (80 ml; fraction D), MeOH/AcOEt (1:19, 120 ml; fraction E), MeOH/AcOEt (1:4, 
160 ml; fraction F), MeOH/AcOEt (1:1, 80 ml; fraction G), and MeOH (150 ml; fraction H). The 
combined fractions C and D were further purified by SiO2 column chromatography (3 × 17 cm) using 
an n-hexane/AcOEt (3:2, 1:1, 1:5, 30 ml each) gradient that afforded 24 fractions. Fractions 2–8 
contained mitragynine (1343 mg, 66% based on the crude base, [α]D24: –126° {c 1.2, CHCl3}) and 
fractions 18–22 yielded 7-hydroxymitragynine (40 mg, 2% based on the crude base, [α]D23: + 47.9° {c 
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0.55, CHCl3}). From fraction E, paynantheine (178 mg, 8.9% based on the crude base, [α]D25: + 29.4° 
(c 1.2, CHCl3}) was obtained. Fraction F afforded speciogynine (132 mg, 6.6% based on the crude 
base, [α]D24: + 26.8° (c 0.85, CHCl3}). Fraction G was subjected to MPLC (SiO2, 2.5 × 10 cm) with 
MeOH/CHCl3 (1:9, 3 mL/min) to provide speciociliatine (tR: 18 min, 15 mg, 0.8% based on the crude 
base, [α]D24: –10.5° (c 1.2, CHCl3}). The isolated compounds were identified by direct comparison 
with the corresponding authentic samples. The purity (> 99%) of the above compounds was checked 
by HPLC and 1H-NMR (500 MHz) analyses. 
 
Chemistry 
 
To investigate the structure-activity relationship, mitragynine was isolated from the extract of 
leaves of Mitragyna speciosa. Mitragynine-related indole alkaloids (Figure 2) were synthesized from 
mitragynine as described previously (Takayama et al., 2002, 2004). The purity (> 99%) of these 
compounds was checked by HPLC and 1H-NMR (500 MHz) analysis (Takayama et al., 2002). 
 
Drugs 
 
The drugs used in this study were acetylcholine chloride (Dai-ichi Pharmaceutical Co., Tokyo, 
Japan), atropine sulfate (Nacalai Tesque Inc., Tokyo, Japan), tetrodotoxin (Sankyo, Tokyo, Japan), 
morphine hydrochloride (Takeda Chemical Industries, Osaka, Japan), and naloxone hydrochloride 
(Sigma Chemical Co., St. Louis, USA). For bioassays, mitragynine-related alkaloids were first 
dissolved in 100% dimethylsulfoxide to yield a 10 mM solution and then subsequently diluted with 
distilled water. Other drugs were dissolved in distilled water. 
 
Statistical analysis 
 
The data are expressed as the mean ± S.E.M. Statistical analyses were performed with two-tailed 
t-test for comparison of two groups, and by a one-way analysis of variance, followed by a Bonferroni 
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multiple comparison test for comparison of more than two groups. A P value < 0.05 was considered 
statistically significant. 
 
 
3. Results 
 
Effect of crude extract on electrically-stimulated twitch contraction 
 
First, the opioid agonistic activity of the crude extract of Mitragyna speciosa was evaluated using 
the twitch contraction induced by electrical stimulation in guinea-pig ileum. The crude extract (1−300 
µg/ml) inhibited the twitch contraction in a concentration-dependent manner (Table 1). The effect of 
the opioid receptor antagonist naloxone on the contraction inhibition was examined to verify that the 
extract acts on opioid receptors. The effect of the crude extract was reversed by naloxone (Table 2). 
Naloxone (30−300 nM) also inhibited the effect of morphine, but did not affect the effect of verapamil, 
an L-type Ca2+ channel blocker, on the twitch contraction (Table 2), suggesting that the antagonistic 
effect of naloxone is specific to the opioid receptors. 
This crude extract was successively fractionated into crude base, n-BuOH, and water fractions. 
Among them, only the crude base extract was found to exhibit the inhibition of the twitch contraction 
(Table 1). The inhibitory effect was concentration-dependent (1−100 µg/ml). The AcOH-insoluble, 
n-BuOH and water-soluble fractions (10−300 µg/ml) showed hardly any effect on ileal twitch 
contraction. 
Silica gel column chromatography of the crude base fraction isolated five alkaloids: 
7-hydroxymitragynine, mitragynine, speciogynine, speciociliatine, and paynantheine (Figure 1). Each 
alkaloid inhibited the electrically-induced twitch contraction in a concentration-dependent manner. 
Among them, 7-hydroxymitragynine showed the most potent effect on the ileal contraction (Table 1). 
The potency was 30 and 17 fold higher than that of mitragynine and morphine, respectively. Naloxone 
(30, 300 nM) restored the twitch contraction inhibited by 7-hydroxymitragynine (Table 2). 
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Figure 1 Chemical structures of constituents of Mitragyna speciosa. 
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Table 1 Opioid agonistic activities of extracts and constituents of Mitragyna speciosa in guinea-pig ileum 
preparation  
Compound      pD2 Value   Relative     Maximum        Relative Inhibitory 
Potency (%)  Inhibition (%)     Activity (%) 
Morphine (positive control)  7.15 ± 0.05      100      87.2 ± 1.8 c    100   
Crude extract    5.05 ± 0.24    0.8      42.3 ± 6.0 b     49   
Crude base fraction   4.32 ± 0.15    0.1       72.5 ± 8.1 c     83   
n-BuOH fraction   NE      NE        -11.3 ± 4.0 a        -13   
AcOH-insoluble fraction  NE      NE      13.6 ± 8.9     16   
Water-soluble fraction   NE      NE        -12.3 ± 7.3        -14   
7-Hydroxymitragynine  8.38 ± 0.12   1698       86.3 ± 4.8 c     99   
Mitragynine     6.91 ± 0.04     58       84.0 ± 2.0 c     96   
Speciogynine     5.61 ± 0.06      3       75.1 ± 8.3 c     86   
Paynantheine     4.99 ± 0.06      1       74.9 ± 5.0 c     86  
Speciociliatine     5.55 ± 0.15      3       86.3 ± 2.1 c     99   
Effects of samples on electrically-induced twitch contraction were examined in guinea-pig ileum. Potency is expressed as the 
pD2 value, which is the negative logarithm (–log g/ml for extracts, –log M for compounds) of the concentration required to 
produce 50% of the maximum response to each compound (EC50). Relative potency is expressed as a percentage of the pD2 
value of each compound against that of morphine. Maximum inhibition (%), which is elicited by the compound when the 
response reaches a plateau, was calculated by regarding the twitch contraction as 100%. Relative inhibitory activity, which 
means intrinsic activity on opioid receptors, is expressed as a percentage of the maximum inhibition by each compound 
against that by morphine. Each value represents mean ± S.E.M. of five animals. When significant inhibition was not 
obtained at 30 µM of the compound, the effect was recorded as “not effective (NE)”. a P < 0.05, b P < 0.01, c P < 0.001, 
significantly different from the values before the addition of each compound.  
 
 
 
Table 2 Effects of naloxone on twitch contraction inhibited by crude extract and constituents of Mitragyna 
speciosa in guinea-pig ileum preparation  
Compound     (Concentration) Contraction (%)   Contraction (%) 
Inhibited by Samples   Reversed by Naloxone  
                   30 nM     300 nM  
Crude extract     (300 µg/ml) 56.5 ± 11.2      65.7 ± 8.4    83.2 ± 5.2 b  
7-Hydroxymitragynine  (100 nM)   24.4 ± 4.4      56.3 ± 8.2 b    129.5 ± 8.1 c  
Mitragynine    (3 µM)   18.9 ± 2.3      29.9 ± 2.5    117.4 ± 5.7 c  
Speciogynine     (30 µM)   22.6 ± 9.1      25.9 ± 9.0    42.3 ± 12.0  
Paynantheine     (30 µM)   43.0 ± 5.8      42.4 ± 5.8    41.6 ± 6.5  
Speciociliatine     (30 µM)   25.2 ± 6.4      19.1 ± 5.4    25.2 ± 5.2  
Morphine      (1 µM)   15.3 ± 2.0      68.0 ± 5.3 c    121.6 ± 6.1 c  
Verapamil     (3 µM)   7.9 ± 2.6       7.9 ± 2.6    6.1 ± 1.6  
Each value represents mean ± S.E.M. of five animals. b P < 0.01, c P < 0.001, significantly different from the values before 
the addition of naloxone. 
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Effects of mitragynine-related indole alkaloids on electrically-stimulated twitch contraction 
 
The opioid agonistic activities of the natural analogue of mitragynine and semi-synthetic 
compounds derived from mitragynine were evaluated by measuring the twitch contraction induced by 
electrical stimulation in the guinea-pig ileum preparation (Table 3). Mitragynine inhibited the twitch 
contraction induced by electrical stimulation at a potency of about 58% of that of morphine. In 
investigating the structure-activity relationship, we initially directed our attention to the presence of a 
methoxyl group at the C9 position on the indole ring in mitragynine. The 9-demethoxy analogue of 
mitragynine, corynantheidine, did not show any opioid agonistic activity at all, but reversed the 
morphine-inhibited twitch contraction in guinea-pig ileum. Its antagonistic effect was 
concentration-dependent (data not shown). The 9-demethyl analogue of mitragynine, 
9-hydroxycorynantheidine, also inhibited the electrically-induced twitch contraction, but its maximum 
inhibition percentage was lower than that of mitragynine. 9-Acetoxymitragynine produced a marked 
reduction of both intrinsic activity and potency compared with those of mitragynine. 
9-Methoxymethylcorynantheidine did not show any opioid agonistic activities.  
Next, we investigated the transformation of the substituent at C7 position. 7-Hydroxymitragynine 
inhibited the electrically-stimulated twitch contraction in a concentration-dependent manner, as 
mitragynine and morphine did. The pD2 values were 8.38 ± 0.12 for 7-hydroxymitragynine, 6.91 ± 
0.04 for mitragynine and 7.15 ± 0.05 for morphine. The introduction of a methoxy, ethoxy, or acetoxy 
group at the C7 position (7-methoxymitragynine, 7-ethoxymitragynine, or 7-acetoxymitragynine) led 
to a marked reduction in both maximum inhibition and relative potency of the opioid receptors (Table 
3). The pD2 values were 6.45 ± 0.04 for 7-methoxymitragynine, 5.29 ± 0.12 for 7-ethoxymitragynine, 
and 6.50 ± 0.16 for 7-acetoxymitragynine. 
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Figure 2 Chemical structures of mitragynine-related indole alkaloids 
 
 
 
 
Table 3 Opioid agonistic activities of mitragynine-related compounds and morphine in electrically-stimulated 
guinea-pig ileum preparation 
Compound       pD2 Value   Relative      Maximum       Relative Inhibitory 
Potency (%)   Inhibition (%)    Activity (%) 
Morphine (positive control)   7.15 ± 0.05    100       87.2 ± 1.8 c     100  
Mitragynine      6.91 ± 0.04    58       84.0 ± 2.0 c  96   
Corynantheidine     NE      NE        -18.1 ± 8.6      NE  
9-Hydroxycorynantheidine   6.78 ± 0.23    41      49.4 ± 3.1 c    57    
9-Acetoxycorynantheidine    5.39 ± 0.12    2       33.2 ± 8.8 c  38  
9-Methoxymethylcorynantheidine NE     NE      NE          NE  
7-Hydroxymitragynine   8.38 ± 0.12    1698       86.3 ± 4.8 c  99   
7-Methoxymitragynine    6.45 ± 0.04    19       60.9 ± 0.2 b        70   
7-Ethoxymitragynine    5.29 ± 0.12    1       22.9 ± 1.1 c  26   
7-Acethoxymitragynine   6.50 ± 0.16    21       13.4 ± 12.7 c  15  
Opioid agonistic activities of the compounds were evaluated by their ability to inhibit the electrically-induced twitch 
contraction, which was reversed by naloxone (300 nM). Relative potency is expressed as a percentage of the pD2 value of 
the compound against that of morphine. Maximum inhibition (%), which is elicited by the compound when the response 
reaches a plateau, was calculated by regarding electrically-induced contraction as 100%. Relative inhibitory activity, which 
means intrinsic effect on opioid receptors, is expressed as a percentage of the maximum inhibition by compounds against 
that by morphine. Each value represents mean ± S.E.M. of five to six animals. b P < 0.01, c P < 0.001, significantly different 
from the morphine group. When significant inhibition was not obtained at 30 µM of the compound, the effect was regarded 
as “no effect” (NE). 
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4. Discussion  
 
Opioid effect of extract 
 
Mitragyna speciosa has been traditionally used as a substitute for opium in tropical areas (Jansen 
and Prast, 1988). We found that mitragynine, a major constituent of this plant, elicits an opioid 
agonistic effect in guinea-pig ileum (Watanabe et al., 1997; Yamamoto et al, 1999). In the present 
study, we attempted to find opioid agonistic principles other than mitragynine. The opioid agonistic 
activities of the crude and fraction extracts were evaluated using the twitch contraction induced by 
electrical stimulation in guinea-pig ileum. The crude extract inhibited the twitch contraction, which 
was reversed by naloxone. This result demonstrates that it has an opioid agonistic effect. 
 
Opioid effect of alkaloids 
 
Based on the results of activities of various fractions, the active components were extracted from 
the crude base fraction. This fraction extract was chromatographed to yield five compounds. They 
were identified as 7-hydroxymitragynine, mitragynine, speciogynine, paynantheine, and 
speciociliatine by direct comparison with corresponding authentic samples. Each alkaloid inhibited 
the electrically-induced twitch contraction in a concentration-dependent manner. The opioid agonistic 
effect of mitragynine was also obtained as reported previously (Watanabe et al., 1997; Yamamoto et 
al., 1999). 7-Hydroxymitragynine is an oxidized derivative of mitragynine and a minor constituent of 
the leaves of Mitragyna speciosa (Ponglux et al., 1994). The inhibitory effect of 
7-hydroxymitragynine was abolished by naloxone, suggesting the involvement of opioid receptors. 
Among the components isolated in this study, 7-hydroxymitragynine exhibited the most potent 
activity. The potency, calculated using pD2 values, was about 30 and 17 fold higher than that of 
mitragynine and morphine, respectively. Taken together with this potency, it is suggested that the 
opioid effect of Mitragyna speciosa is based on the activity of 7-hydroxymitragynine. 
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Opioid effect of mitragynine-related alkaloids 
 
The discovery of the potent opioid effects of mitragynine and 7-hydroxyitragynine, prompted us 
to embark on the synthesis of novel lead compounds based on the mitragynine skeleton. We initially 
directed our attention to a methoxy group at the C9 position on the indole ring in mitragynine, 
because it is a structural characteristic of Mitragyna alkaloids, compared with common 
Corynanthe-type indole alkaloids isolated from other plants (Lounasmaa et al., 1994). It is interesting 
that a transformation of the substituent at C9, i.e., from OMe to H, led to a shift of intrinsic activity 
from a full agonist to an antagonist of opioid receptors. Thus, it was found that the functional group at 
C9 of mitragynine-related compounds manages the relative inhibitory activity, which means the 
intrinsic activity on opioid receptors. The introduction of an acetoxy group at C9 on the indole ring 
(9-acetoxymitragynine) led to marked reduction of both intrinsic activity and potency compared with 
those of mitragynine. The 9-demethyl analogue of mitragynine, 9-hydroxycorynantheidine, inhibited 
electrically-induced twitch contraction, but its maximum inhibition was about 50%, lower than that of 
mitragynine. Therefore, it is speculated that 9-hydroxycorynantheidine may possess partial agonist 
properties. 9-Methoxymethylcorynantheidine did not show any opioid agonistic activities. The present 
results demonstrate that the intrinsic activities of the compounds on opioid receptors are determined 
by the functional groups at the C9 position, and that a methoxy group at the C9 position is the most 
suitable functional group for pharmacophore binding to opioid receptors.  
7-Hydroxymitragynine, a minor constituent of Mitragyna speciosa, was found to exhibit high 
potency toward opioid receptors. The intrinsic activity of 7-hydroxymitragynine suggests its full 
agonistic effect on opioid receptors. The introduction of a hydroxyl group at the C7 position led to a 
higher potency compared with mitragynine. Therefore, we directed our attention to the transformation 
of the substituent at the C7 position. The introduction of a methoxy, ethoxy, or acetoxy group at the 
C7 position led to a marked reduction in both intrinsic activity and potency toward opioid receptors. 
These results suggest that the hydroxyl group at the C7 position in the mitragynine skeleton is 
necessary for the increased potency toward opioid receptors.  
In the course of our study, we investigated the constituents of Mitragyna speciosa and 
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semi-synthetic compounds derived for mitragynine. Among them, we found two interesting 
compounds. One is 7-hydroxymitragynine, which showed the most potent effect in the constituent in 
of Mitragyna speciosa and mitragynine-related compounds. The other is 9-hydroxycorynantheidine, 
which possesses partial agonist properties. In the search for alternative analgesics for morphine, 
opioids showing a partial agonist profile have yielded good results. For example, buprenorphine, a 
partial opioid agonist, is used clinically to treat pain, and more recently, it has been used as an 
alternative to methadone in maintenance and detoxification of heroin addicts (Bickel et al., 1988; 
Kosten and Kleber, 1988). In the next chapter, we investigate the full and partial agonist characters of 
7-hydroxymitragynine and 9-hydroxycorynantheidine, respectively.  
 
 
Summary 
 
In the present chapter, we described the opioid effects of constituents isolated from Mitragyna 
speciosa and semi-synthetic compounds derived from mitragynine. Among them, 
7-hydroxymitragynine showed the most potent opioid effect, which was 17 fold more potent than that 
of morphine. 9-Hydroxycorynantheidine, a 9-demethyl analogue of mitragynine, showed a partial 
agonistic effect on opioid receptors in guinea-pig ileum. 
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Part ΙΙ. Elucidation of opioid effect of 7-hydroxymitragynine and 
9-hydroxycorynanthidine by in vitro assays 
 
1. Introduction 
 
In chapter Ι, we surveyed opioid activity of constituents isolated from Mitragyna speciosa and 
found that a minor constituent 7-hydroxymitragynine exhibited about 17 fold higher potency than 
morphine in the guinea-pig ileum test. It was also found that the functional group at C9 of 
mitragynine-related compounds controls the maximum activity, which means the intrinsic activity on 
opioid receptors. The 9-demethyl analogue of mitragynine, 9-hydroxycorynantheidine, inhibited 
electrically induced twitch contraction in guinea-pig ileum, but its maximum inhibition was about 
50%, lower than that of mitragynine. Therefore, it is speculated that 9-hydroxycorynantheidine may 
possess partial agonist properties (Takayama et al., 2002). However, it has not yet been determined 
whether 9-hydroxycorynantheidine is a partial agonist on opioid receptors.  
In the present chapter, we examined the partial agonistic character of 9-hydroxymitragynine and 
involvement of the opioid receptor subtypes on the inhibitory effect of 7-hydroxymitragynine and 
9-hydroxycorynantheidine in isolated guinea-pig ileum, mouse vas deferens contraction and receptor 
binding assays. 
 
 
2. Materials and methods  
 
Animals 
 
All experiments were performed in compliance with the “Guiding Principles for the Care and 
Use of Laboratory Animals” approved by the Japanese Pharmacological Society. The number of 
animals used was kept to the minimum necessary for a meaningful interpretation of the data, and 
animal discomfort was kept to the minimum. Male albino guinea pigs (320–540 g, Takasugi Lab. 
Animals, Japan) and male ddY mice (30–45 g, SLC, Japan) were killed by CO2 inhalation.  
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 Isolation of guinea-pig ileum 
 
The guinea-pig ileum was dissected and placed in Krebs-Henseleit solution (mM): NaCl, 112.08; 
KCl, 5.90; CaCl2, 1.97; MgCl2, 1.18; NaH2PO4, 1.22; NaHCO3, 25.00 and glucose, 11.49. The ileum 
was placed under 1 g tension in a 5 ml organ bath containing the nutrient solution. The bath was 
maintained at 37ºC and continuously bubbled with a mixture of 95% O2 and 5% CO2. Tissues were 
stimulated by a platinum needle-ring (the ring was placed 20 mm above the base of a needle 5 mm in 
length) electrode. After 60 min equilibration in Krebs-Henseleit solution, the ileum was transmurally 
stimulated (Cox and Weinstock, 1966) with monophasic pulses (0.2 Hz and 0.1 ms duration) by a 
stimulator (SEN-7203, Nihon Kohden, Tokyo, Japan). Contractions were isotonically recorded by 
using a displacement transducer (NEC Type 45347, San-ei Instruments Ltd., Tokyo, Japan). The 
effects of drug treatments on the twitch contractions evoked by transmural stimulation elicited 
through the ring electrodes were examined. At the start of each experiment, a maximum response to 
acetylcholine (3 µM) in each tissue was obtained to check its stability. The mean amplitude of the 
electrically stimulated contraction was about 30% of the maximal response to acetylcholine (3 µM). 
The electrically induced twitch contraction was almost abolished by tetrodotoxin (1 µM) and atropine 
(0.1 µM), as described previously (Watanabe et al., 1997). Thus, the electrical stimulation induced 
cholinergic contraction in guinea-pig ileum (Brookes et al., 1991). The height of the twitch response 
to transmural stimulation was measured before and after the drug challenge. All 
concentration-response curves were constructed in a cumulative manner. Contraction (%) is expressed 
as a percentage of the twitch response to the transmural stimulation before the drug challenge. The 
apparent agonist efficacies (intrinsic activity) were determined by comparing the maximum effect of 
mitragynine (intrinsic activity = 1.00). 
β-Funaltorexamine hydrochloride (β-FNA) exhibits irreversible µ-opioid antagonistic and 
short-lived reversible agonistic profiles (Portoghese et al., 1980; Takemori et al., 1981). To investigate 
the effects of test compounds on µ-opioid receptors, the ileum was preincubated with β-FNA, a 
selective µ-opioid receptor antagonist, at 10, 30 or 100 nM for 30 min, and then it was washed 20 
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times with Krebs-Henseleit solution. In addition, it was washed the again at 15 min intervals for 60 
min to remove the opioid receptor agonistic action of β-FNA (Ozaki et al., 1994). 
 
Isolation of mouse vas deferens 
 
The mouse vas deferens was dissected and placed in eliminating MgCl2 from Krebs-Henseleit 
solution. The tissues were placed under 0.2 g tension in a 5 ml organ bath containing the nutrient 
solution. The bath was maintained at 37ºC and continuously bubbled with a mixture of 95% O2 and 
5% CO2. Tissues were stimulated by a platinum needle-ring (the ring was placed 20 mm above the 
base of a needle 5 mm in length) electrode. After 60 min equilibration in Krebs-Henseleit solution, the 
tissues were transmurally stimulated with a train of 10 pulses, 0.5 msec duration, 2 msec interval by a 
stimulator (SEN-7203, Nihon Kohden, Tokyo, Japan) every 1 min. Contractions were isotonically 
recorded by using a displacement transducer (NEC Type 45347, San-ei Instruments Ltd., Tokyo, 
Japan). The effects of drug treatments on the twitch contractions evoked by transmural stimulation 
elicited through the ring electrodes were examined. At the start of each experiment, a maximum 
response to norepinephrine (30 µM) with 0.1 mM ascorbic acid in each tissue was obtained to check 
its stability. All concentration-response curves were constructed in a cumulative manner. The height of 
the twitch response to transmural stimulation was measured before and after the drug challenge. 
Contraction (%) is expressed as a percentage of the twitch response to the transmural stimulation 
before the drug challenge. 
 
Receptor binding assay 
 
The whole male guinea-pig brain (excluding the cerebellum) was quickly removed, weighed, 
placed in ice cold 50 mM Tris-HCl buffer, pH 7.4, and frozen immediately. Frozen brains were stored 
at −70ºC until the assay. For each experiment, frozen brains from two animals were thawed and 
homogenized with a Polytron homogenizer (PT 10-35, Kinematica, Littau, Switzerland) for 60 sec in 
50 mM Tris-HCl (pH 7.4) and centrifuged at 49,000 g for 10 min (Childers et al., 1979). The pellet 
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was re-homogenized and centrifuged again. For the binding assays, membrane fractions were 
suspended in the assay buffer. The protein concentration was measured by using a DC-protein assay 
kit (Bio-Rad, Richmond, VA, USA).  
Saturation-binding isotherms were produced by incubating membrane proteins with radiolabeled 
compounds in different concentrations. Using the above solution, 0.1 ml aliquots of protein were 
added to 0.9 ml of solutions of the labeled assay sample with unlabeled competing ligands, which 
were dissolved in 50 mM Tris-HCl, pH 7.4, assay buffer, in appropriate concentrations. The assay 
solution contained one of the followings; 3 nM of [3H][D-Ala2, N-MePhe4, Gly-ol5]-enkephalin 
([3H]DAMGO), 3 nM of [3H](5α,7α,8β)-(+)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro 
[4.5]dec-8-yl]-benzeneacetamide ([3H]U69593) or 1 nM of [3H][D-Pen2, D-Pen5]-enkephalin 
([3H]DPDPE). The incubation periods were 3, 4 and 1 hr for [3H]DAMGO, [3H]DPDPE and 
[3H]U69593, respectively, at 25ºC. The reaction was terminated by rapid filtration under reduced 
pressure through glass fiber filters (Whatman GF/B, presoaked in 0.3% polyethyleneimine), followed 
by the addition of 4 ml of ice-cold Tris-HCl buffer. Filters were further washed with 4 ml ice-cold 
buffer and allowed to dry. The radioactivity bound to the filters was measured by liquid scintillation 
spectrometry (Aloka LSC-5100, Tokyo, Japan). Nonspecific binding for [3H]DAMGO, [3H]DPDPE 
or [3H]U69593 was determined in the presence of 1 µM unlabeled DAMGO, naltrindole 
hydrochloride and U69593, respectively. All values were presented as the mean ± S.E.M. The 
apparent dissociation constant (KD) and maximum binding site density (Bmax) for radioligands were 
estimated by Scatchard analysis of the saturation. The ability of unlabeled drugs to inhibit specific 
radioligand binding was expressed as the IC50 value, which was the molar concentration of the 
unlabeled drug necessary to displace 50% of the specific binding. Inhibition constants (Ki) of 
unlabeled compounds were calculated as described by Cheng and Prusoff (1973). Relative affinities 
(%) of 7-hydroxymitragynine and 9-hydroxycorynantheidine for µ-, δ- and κ-opioid receptors were 
calculated according to the following equations:  
(%)100
for  Kafor  Kafor  Ka
,,for  Ka(%)affinity  Relative ×++= κδµ
κδµ
     
(Ka = 1 / Ki) 
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 Drugs 
 
The drugs used in this study were acetylcholine chloride (Dai-ichi Pharmaceutical Co., Tokyo, 
Japan), norepinephrine bitartarate (Wako, Osaka, Japan), DPDPE (Bachem, Torrance, CA), naloxone 
hydrochloride, DAMGO, U69593, naltrindole hydrochloride (Sigma Chemical Co., St. Louis, MO, 
USA), β-funaltorexamine hydrochloride (Research Biochemicals, Natick, MA, USA) and 
[3H]DAMGO, [3H]DPDPE and [3H]U69593 (NEN Life Science Products Inc., Boston, MA, USA). 
Mitragynine was isolated from the extract of leaves of Mitragyna speciosa. 7-Hydroxymitragynine 
and 9-hydroxycorynantheidine were synthesized from mitragynine as described previously (Takayama 
et al., 2002). The purity (> 99%) of these compounds was checked by HPLC and 1H-NMR (500 MHz) 
analysis (Takayama et al., 2002). 
Mitragynine, 7-hydroxymitragynine, and 9-hydroxycorynantheidine were first dissolved in 100% 
dimethylsulfoxide to yield a 10 mM solution and then subsequently diluted with distilled water. 
β-Funaltorexamine hydrochloride were first dissolved in 100% dimethylsulfoxide to yield a 1 mM 
solution, and then subsequently diluted with distilled water. Other drugs were dissolved in distilled 
water.  
 
Statistical analysis 
 
The data are expressed as the mean ± S.E.M. Statistical analyses were performed with two-tailed 
Student’s t-test for comparison of two groups, and by a one-way analysis of variance, followed by a 
Bonferroni multiple comparison test for comparison of more than two groups. A P value < 0.05 was 
considered statistically significant. 
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 3. Results 
 
Effect of 7-hydroxymitragynine and 9-hydroxycorynantheidine on electrically induced contraction in 
guinea-pig ileum 
 
The inhibitory effects of morphine, mitragynine, 7-hydroxymitragynine, and 
9-hydroxycorynantheidine on twitch contraction induced by electrical stimulation in guinea-pig ileum 
are shown in Figure 1A. The addition of 7-hydroxymitragynine inhibited the electrically stimulated 
twitch contraction in a concentration-dependent manner as mitragynine and morphine did. Typical 
recording of the effect of 7-hydroxymitragynine is shown in Figure 1B. The pD2 values were 7.78 ± 
0.08 for 7-hydroxymitragynine, 6.50 ± 0.06 for mitragynine and 7.02 ± 0.08 for morphine. 
Consequently, 7-hydroxymitragynine exhibits about 13 and 46 fold higher potency than morphine and 
mitragynine, respectively. Naloxone reversed the inhibitory effect of 300 nM 7-hydroxymitragynine 
(control, 32.8 ± 5.3%; naloxone 10 nM, 51.7 ± 10.2%; naloxone 300 nM, 108.0 ± 5.3%, P<0.001 vs. 
control) as well as that of morphine (control, 22.3 ± 7.8%; naloxone 10 nM, 37.0 ± 9.8%; naloxone 
300 nM, 133.0 ± 13.5%, P < 0.001 vs. control, Data represent mean ± S.E.M. of five animals). 
9-Hydroxycorynantheidine, the 9-demethyl analogue of mitragynine, inhibited the electrically 
stimulated ileum contraction, but its maximum inhibition (intrinsic activity = 0.56) was lower than 
that of mitragynine. Naloxone reversed the inhibitory effect of 3 µM 9-hydroxycorynantheidine 
(control, 49.2 ± 5.0%; naloxone 10 nM, 60.9 ± 6.8%; naloxone 300 nM, 110.6 ± 4.1%, P < 0.001 vs. 
control, Data represent mean ± S.E.M. of five animals). 7-Hydroxymitragynine (300 nM) and 
9-hydroxycorynantheidine (3 µM) did not affect the concentration-response curve for acetylcholine in 
the ileum (data not shown). These results suggest that both 7-hydroxymitragynine and 
9-hydroxycorynantheidine have opioid agonistic activity in the guinea-pig ileum test.  
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Figure 1 (A) Concentration-response curves for inhibitory effects of morphine (○), mitragynine (●), 
7-hydroxymitragynine (▲) and 9-hydroxycorynantheidine (■) on electrical stimulation-induced contraction in 
guinea-pig ileum. Each value is expressed as inhibition % of the transmurally stimulated twitch contraction 
before the addition of samples. Data represent mean ± S.E.M. of five animals. (B) Typical recording of the effect 
of 7-hydroxymitragynine on electrical stimulation-induced in the guinea-pig ileum. 
 
 
Involvement of µ-opioid receptor subtypes in the opioid effect of 7-hydroxymitragynine and 
9-hydroxycorynantheidine 
 
The guinea-pig ileum tissue contains predominantly µ-and κ-opioid receptors, while mouse vas 
deferens includes δ-opioid receptors. We investigated the involvement of the µ- and κ- opioid 
receptors in the effect of 7-hydroxymitragynine and 9-hydroxycorynantheidine using guinea-pig 
ileum and mouse vas deferens. The pA2 values for naloxone in the response curves for DAMGO, 
U69593, 7-hydroxymitragynine and 9-hydroxycorynantheidine were compared in guinea-pig ileum 
test (Table 1). In the absence of naloxone, 7-hydroxymitragynine, 9-hydroxycorynantheidine, 
DAMGO, and U69593 inhibited the contraction. The concentration-response curves for 
7-hydroxymitragynine, 9-hydroxycorynantheidine, DAMGO, and U69593 were shifted to the right in 
the presence of naloxone (data not shown). The slope factors for 7-hydroxymitragynine, 
9-hydroxycorynantheidine, DAMGO, and U69593 were not significantly different from a unity, 
suggesting their competitive inhibition. The pA2 values of naloxone were 8.95 ± 0.30 for 
7-hydroxymitragynine, 8.69 ± 0.31 for 9-hydroxycorynantheidine, 8.77 ± 0.35 for DAMGO, and 7.50 
± 0.36 for U69593. 
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Table 1 pD2 values for inhibition of electrically stimulated contraction by 7-hydroxymitragynine, 
9-hydroxycorynantheidine, DAMGO and U69593 in guinea-pig ileum, and pA2 values of naloxone against 
7-hydroxymitragynine, 9-hydroxycorynantheidine, DAMGO and U69593 
       pD2    pA2    Slope 
7-Hydroxymitragynine   7.78 ± 0.08  8.95 ± 0.30  0.91 ± 0.20  
9-Hydroxycorynantheidine  6.56 ± 0.07  8.69 ± 0.31  0.93 ± 0.16  
DAMGO      7.83 ± 0.07  8.77 ± 0.35  1.18 ± 0.18  
U69593      9.01 ± 0.12  7.50 ± 0.36  1.19 ± 0.09 
pD2 values are the negative logarithm of the IC50 values. The pA2 values are calculated from parallel shifts of the curves for 
the agonists. Data are expressed as the mean ± S.E.M. of five animals. 
 
 
 
To investigate the involvement of δ-receptor in the opioid effect of 7-hydroxymitragynine and 
9-hydroxycorynantheidine, compounds were tested in the electrically stimulated mouse vas deferens 
assays using δ-opioid selective antagonist (Table 2). Naltrindole (30 nM), a δ-opioid receptor 
antagonist, completely reversed the inhibitory effect of DPDPE, but did not reverse the effect of 
7-hydroxymitragynine, 9-hydroxycorynantheidine, DAMGO, and U69593. 
 
 
Table 2 Effect of naltrindole on twitch contraction inhibited by 7-hydroxymitragynine, 
9-hydroxycorynantheidine, DAMGO and U69593 in mouse vas deferens   
Compound (Concentration)    Contraction (%)      Contraction (%) 
Inhibited by Compounds  Reversed by naltrindole  
                   3 nM   30 nM  
7-Hydroxymitragynine (300 nM)   7.8 ± 1.5        8.4 ± 1.9    18.9 ± 2.9 a  
9-Hydroxycorynantheidine (10 µM)   57.4 ± 8.4       57.7 ± 8.8   56.5 ± 8.3 
DPDPE (100 nM)      12.1 ± 3.2       42.5 ± 8.0 b  83.8 ± 2.9 c  
DAMGO (300 nM)      11.9 ± 2.1       13.8 ± 3.3  19.4 ± 3.6   
U69593 (1 µM)      19.1 ± 4.8       21.4 ± 5.2   24.0 ± 6.9  
Each value represents mean ± S.E.M. of five animals. a P < 0.05, b P < 0.01, c P < 0.001, significantly different from the 
values before the addition of naltrindole. 
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Partial agonistic effect of 9-hydroxycorynantheidine on µ-opioid receptors in guinea-pig ileum 
 
To determine the partial agonistic activity of 9-hydroxycorynantheidine on µ-opioid receptors in 
the guinea-pig ileum, selective agonist and antagonist were used. 9-Hydroxycorynantheidine (30−300 
nM) slightly shifted the concentration-response curve for DAMGO to the right, and the pA2 value was 
7.12 ± 0.31 (Figure 2). The slope factor for DAMGO (1.36 ± 0.48) was not significantly different 
from unity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Concentration-response curves for DAMGO on electrical stimulation-induced contraction of 
guinea-pig ileum in the absence (○) or presence of 9-hydroxycorynantheidine (30 nM, ■; 100 nM, ▲; 300 nM, 
●). Responses are expressed as inhibition % of the twitch contraction before agonist addition. Data represent 
mean ± S.E.M. of five animals. 
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The agonistic effect of 9-hydroxycorynantheidine was evaluated by using the µ-opioid-selective 
and irreversible antagonist β-FNA (Figure 3). Pretreatment with β-FNA (10−100 nM) shifted the 
concentration-response curve for DAMGO to the right in a competitive manner without affecting the 
maximum response. On the other hand, pretreatment with β-FNA (10−100 nM) did not shift the curve 
of 9-hydroxycorynantheidine and decreased the maximum response to 34%. 
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Figure 3 Concentration-response curves for (A) DAMGO and (B) 9-hydroxycorynantheidine on electrical 
stimulation-induced contraction in guinea-pig ileum in the absence (○) or the presence of β-funaltorexamine 
hydrochloride (β-FNA) (10 nM, ■; 30 nM, ▲; 100 nM, ●). Responses are expressed as inhibition % of the 
twitch contraction before agonist addition. Data represent mean ± S.E.M. of five animals. 
 
 
Effect of 7-hydroxymitragynine and 9-hydroxycorynantheidine on opioid-receptor binding in brain 
 
Competition binding assays revealed that both 7-hydroxymitragynine and 
9-hydroxycorynantheidine bound to opioid receptors in homogenates of guinea-pig brain membrane 
(Table 3). The affinities of the compound for three opioid receptor types were determined by 
evaluating the inhibition of binding of ligands to µ-, δ- and κ-opioid receptors. Specific bindings of 
these radioligands for the opioid receptor types were saturable, and Scatchard plots were linear. The 
KD values of [3H]DAMGO, [3H]DPDPE and [3H]U69593 were 1.07 ± 0.06, 0.66 ± 0.05 and 0.87 ± 
0.05 nM, respectively. Further, their Bmax values were 88.2 ± 15, 41.2 ± 0.74 and 78.5 ± 9.8 fmol/mg 
protein, respectively. 
Figure 4 shows displacement curves for the specific binding of [3H]DAMGO, [3H]DPDPE, and 
[3H]U69593 with various concentrations of 7-hydroxymitragynine and 9-hydroxycorynantheidine. 
DAMGO, 7-hydroxymitragynine, and 9-hydroxycorynantheidine bound preferentially to µ-opioid 
receptors with pKi values of 8.73 ± 0.04, 8.01 ± 0.03, and 7.92 ± 0.05, respectively. The relative 
affinities of 7-hydroxymitragynine for µ-, δ-, and κ-opioid receptors were 89.8%, 5.6%, and 4.6%, 
respectively. The affinities of 9-hydroxycorynantheidine were 99.6%, < 0.1% and 0.4%, respectively.  
 29
(A)           (B) 
 
 
 
 
 
 
 
 
 
 
120
100
80
60
40
20
0
Sp
ec
ifi
c 
bi
nd
in
g 
(%
)
-8 -7 -6 -5 -4
7-Hydroxymitragynine(logM)
120
100
80
60
40
20
0
Sp
ec
ifi
c 
bi
nd
in
g 
(%
)
-9 -8 -7 -6 -5 -4 -3
9-Hydroxycorynantheidine(logM)
Figure 4 Displacement curves for (A) 7-hydroxymitragynine and (B) 9-hydroxycorynantheidine on specific 
binding of [3H]DAMGO (●), [3H]DPDPE (▲) and [3H]U69593 (■) in guinea-pig brain homogenates. Each 
value is expressed as a percentage of the specific binding in the absence of 9-hydroxycorynantheidine. Data 
represent mean ± S.E.M. of five independent experiments performed in triplicate. 
 
 
Table 3 Binding affinities (pKi) of 7-hydroxymitragynine and 9-hydroxycorynantheidine to µ-, δ- and κ-opioid 
receptors in homogenates of guinea-pig brain 
       [3H]DAMGO  [3H]DPDPE  [3H]U69593 
7-Hydroxymitragynine   8.01 ± 0.03  6.84 ± 0.12  6.71 ± 0.11 
9-Hydroxycorynantheidine  7.92 ± 0.05  4.51 ± 0.15  5.53 ± 0.15  
DAMGO      8.73 ± 0.04  ND    ND  
Naltrindole     ND    8.61 ± 0.01  ND  
U69593      ND    ND    8.77 ± 0.03 
The values are expressed as the mean ± S.E.M. of five separate displacement curves, each assayed in triplicate. The 
µ-binding sites were labeled with [3H]DAMGO (3 nM), δ-sites with [3H]DPDPE (1 nM) and κ-sites with [3H]U69593 (3 
nM). ND: not determined. 
 
 
4. Discussion  
 
We isolated a new compound, 7-hydroxymitragynine, as a minor constituent of the Thai 
medicinal herb Mitragyna speciosa (Ponglux et al., 1994). In the present study, we investigated its 
opioid effects in an isolated ileum contraction test, a receptor binding assay, and found it to be a 
potent µ-opioid agonist.  
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 Involvement of the opioid receptors on the effect of 7- hydroxymitragynine 
 
The guinea-pig ileum contains populations of functional µ- and κ-opioid receptors (Lord et al., 
1977; Chavkin and Goldstein, 1981). The mouse vas deferens contains populations of functional 
δ-opioid receptors (Hughes et al., 1975). The present chapter showed that 7-hydroxymitragynine 
exhibited inhibitory action on the electrically evoked contractions in the guinea-pig ileum. We 
compared the pA2 values of naloxone on opioid effects of 7-hydroxymitragynine, DAMGO, and 
U69593. The rightward shift of the concentration response curves for 7-hydroxymitragynine in the 
presence of naloxone confirms the opioid effect of 7-hydroxymitragynine. The pA2 values of the 
opioid antagonist naloxone against the inhibitory action of µ selective agonist DAMGO and κ 
selective agonist U69593 represent the affinity of naloxone for µ- and κ-opioid receptors, respectively. 
The pA2 value of naloxone against 7-hydroxymitragynine was very similar to that against DAMGO, 
but clearly different from that against U69593. These results suggested that 7-hydroxymitragynine 
predominantly acts on µ-opioid receptor. To investigate the involvement of δ-opioid receptor in the 
effect of 7-hydroxymitragynine, the mouse vas deferens was used. In the mouse vas deferens, 
7-hydroxymitragynine inhibited the electrically induced contraction but this inhibitory effect did not 
antagonized by the δ-opioid receptor antagonist naltrindole. On the other hand, the inhibitory effect of 
δ-opioid receptor agonist DPDPE completely reversed by naltrindole. Taken together, 
7-hydroxymitragynine induces the opioid effect mainly through the activation of µ-receptors. 
Guinea-pig brain homogenates are commonly used as means of assessing the multiple opioid 
receptor binding spectra of narcotic analgesics. A close correlation between in vitro functional systems 
and opioid receptor binding in the brain has also been suggested (Pert and Snyder, 1973; Lord et al., 
1977). Competition binding assays revealed that 7-hydroxymitragynine bound to opioid receptors in 
homogenates of guinea-pig brain membrane. Its affinities for three opioid receptor types were 
determined by evaluating the inhibition of binding of ligands to µ-, δ- and κ-opioid receptors. As a 
result, 7-hydroxymitragynine interacted with all three opioid sites, but bound preferentially to 
µ-opioid receptors. Taken together, the in vitro results demonstrated that 7-hydroxymitragynine is a 
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full agonist for µ-opioid receptors.  
 
Involvement of the opioid receptors on the effect of 9-hydroxycorynantheidine 
 
The opioid agonistic activities of the constituents of Mitragyna speciosa and semisynthetic 
compounds were evaluated using twitch contraction induced by electrical stimulation. In the course of 
investigating the structure-activity relationship, it was found that the functional group at C9 in 
mitragynine-related compounds determines its maximum activity, which means intrinsic activity on 
opioid receptors. A partial agonist binds to the same active site as the agonist, but elicits only a partial 
biologic response. Therefore, a partial agonist has a lower intrinsic activity than a full agonist. Indeed, 
9-hydroxycorynantheidine behaved as a partial agonist while mitragynine behaved as a full agonist on 
opioid receptors in guinea-pig ileum. The inhibitory effect of 9-hydroxycorynantheidine was 
antagonized by the opioid receptor antagonist naloxone in the guinea-pig ileum, suggesting 
involvement of opioid receptors on the action of 9-hydroxycorynantheidine.  
Next, we compared the pA2 values of the opioid antagonist naloxone against the opioid effects of 
9-hydroxycorynantheidine, DAMGO, and U69593. The rightward shift of the concentration response 
curves for 9-hydroxycorynantheidine in the presence of naloxone confirms the opioid effect of 
9-hydroxycorynantheidine. The pA2 values of naloxone against the inhibitory action of µ-selective 
agonist DAMGO and κ-selective agonist U69593 represent the affinity of naloxone for µ- and 
κ-opioid receptors, respectively. The pA2 value of naloxone against 9-hydroxycorynantheidine was 
very similar to that against DAMGO, but clearly different from that against U69593. Therefore, 
9-hydroxycorynantheidine is thought to act not on κ-opioid receptors, but on µ-opioid receptors. In 
the mouse vas deferens, 9-hydroxycorynantheidine inhibited the electrically induced contraction but 
this inhibitory effect did not antagonized by the δ-opioid receptor antagonist naltrindole. It is 
suggested that 9-hydroxycorynantheidine does not act on δ-opioid receptors. Taken together, 
9-hydroxycorynantheidine inhibited the electrically stimulated contraction selectively through the 
µ-opioid receptors.  
Receptor binding assays revealed that 9-hydroxycorynantheidine binds to opioid receptors in 
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homogenates of guinea-pig brain membrane. Its affinities for three opioid receptor types were 
determined by evaluating the inhibition of binding of ligands to µ-, δ- and κ-opioid receptors. The 
estimated affinity of 9-hydroxycorynantheidine for µ-opioid receptors is approximately 2600 and 250 
times greater than that for δ- and κ-opioid receptors, respectively. As a result, 
9-hydroxycorynantheidine had the high affinity and selectivity for µ-opioid receptors. 
The results obtained in the above two assay systems were in close agreement on the involvement 
of µ-opioid receptors. In general, partial agonists have not only agonistic but also antagonistic effects. 
To determine the µ-opioid partial agonistic properties of 9-hydroxycorynantheidine, we investigated 
the agonistic and antagonistic effect of 9-hydroxycorynantheidine in guinea-pig ileum. 
9-Hydroxycorynantheidine shifted the concentration-response curves for µ-selective agonist DAMGO 
slightly to the right. Logically, a partial agonist antagonizes the pharmacological effect of a full 
agonist, which acts on the same receptor, at the concentration that shows maximal response. Further 
proof for its involvement in the µ-opioid receptor was obtained when ileum was pretreated with the 
irreversible µ-opioid receptor antagonist β-FNA. It is widely accepted that a full maximum response 
was elicited by a full agonist at very low concentrations, which can only occupy certain fractions 
among in all specific receptors present. Those receptors that are unoccupied when a full maximum 
response is already elicited by an agonist are termed “spare receptors”. Drugs with high intrinsic 
activity require fewer drug–receptor interactions than drugs with low intrinsic activity to produce a 
maximal effect leading to the concept of spare receptors (Furchgott, 1966). The irreversible antagonist 
β-FNA, which is used to titrate away spare receptors, shifted the concentration-response curves for 
DAMGO to right in a competitive manner without affecting the maximum response; on the other hand, 
β-FNA did not shift the curve of 9-hydroxycoynantheidine to the right and decreased the maximum 
response at the same concentration range as an antagonist. In general, full agonists do not need to bind 
spare receptors for their maximum effect, and thus full agonists can induce the maximum effect in the 
presence of some concentration of an irreversible antagonist, but partial agonist needs to bind all 
specific receptors inducing spare receptors to elicit maximum response, and the maximum response is 
reduced by the irreversible antagonist. These results demonstrate that 9-hydroxycorynantheidine has 
partial agonist properties in the guinea-pig ileum and that its activity is due to µ-opioid receptor 
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activation. 
 
 
Summary 
 
7-Hydroxymitragynine and 9-hydroxycorynantheidine have selectivity for µ-opioid receptors in 
isolated guinea-pig ileum, mouse vas deferens contraction and receptor binding assays. 
7-Hydroxymitragynine has full agonist and 9-hydroxycorynantheidine has partial agonist properties 
on µ-opioid receptors in vitro assays.  
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Part ΙΙΙ. Antinociceptive and side effects of 7-hydroxymitragynine in mice: 
Discovery of a potent and orally active opioid analgesic 
 
1. Introduction 
 
In our laboratory, pharmacological studies were conducted for the characterization of the 
antinociceptive effect of mitragynine and the extract of Mitragyna speciosa on chemical, pressure, 
and thermal-stimulus pain tests in mice. Mitragynine and the extract showed antinociceptive effects 
on these tests in a dose-dependent manner, but the effects were much less potent than that of morphine. 
We studied the opioid agonistic effects of the constituents of Mitragyna speciosa using in vitro assays. 
Among them, 7-hydroxymitragynine showed most potent opioid effect which was 17 fold more potent 
than that of morphine and 9-hydroxycorynantheidine showed partial agonistic effect on opioid 
receptors. Opioid effects of 7-hydroxymitragynine and 9-hydroxycorynantheidine are due to µ-opioid 
receptor activation in vitro assays. However, the antinociceptive effects of 7-hydroxymitragynine and 
9-hydroxycorynantheidine are not investigated in vivo experiments.  
µ-Opioid agonists represent the major class of strong analgesics, such as morphine, used 
clinically. Morphine plays an important role as a pain-relieving agent, but it has a number of side 
effects, e.g., respiratory depression, nausea, vomiting, constipation, tolerance, and dependence. It is 
well known that chronic administration of opioids such as morphine leads to the development of 
tolerance and dependence (Pasternak, 1993). Constipation becomes a major problem during chronic 
opioid administration (Schug et al., 1992; McQuay et al., 1999; Portenoy et al., 1996), and relief from 
the adverse gastrointestinal effects markedly enhances the quality of life for patients. In the case of 
morphine, the dose required for its analgesic effect is much higher than that required for its 
constipating effects; thus, when morphine is used for analgesia, constipation is not negligible (Megens 
et al., 1998). Suwanlert (1975) reported that the chronic exposure to Mitragyna speciosa elicits 
withdrawal symptoms in humans. However, pharmacological studies on the possible side effects of 
mitragynine-related compounds have been lacking (Jansen and Prast, 1988). 
In the present chapter, we investigated the antinociceptive effect of 7-hydroxymitragynine and 
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9-hydroxycorynantheidine in vivo, comparing that of morphine. We evaluated the effect of 
subcutaneous (s.c.) and oral (p.o.) administration of 7-hydroxymitragynine by using acute thermal 
pain tests in mice. Furthermore, we evaluated the inhibitory effect of gastrointestinal transit, 
development of tolerance, cross-tolerance to morphine, and naloxone-precipitated withdrawal signs in 
mice chronically treated with 7-hydroxymitragynine.  
 
 
2. Materials and methods  
 
Animals 
 
Male ddY-strain mice (Japan SLC, Hamamatsu, Japan) weighing 25–32 g was used. Animals 
were housed in a temperature-controlled room at 24ºC with lights on from 07:00–19:00 and had free 
access to food and water. All experiments were performed in compliance with the “Guiding Principles 
for the Care and Use of Laboratory Animals” approved by the Japanese Pharmacological Society. The 
number of animals used was kept to the minimum necessary for a meaningful interpretation of the 
data, and animal discomfort was kept to the minimum. 
 
Antinociceptive activity 
 
Tail-flick test 
 
The method was adapted from that of D’Amour and Smith (1941). Mice respond to a focused 
heat stimulus by flicking or moving their tail from the path of the stimulus, thereby exposing a 
photocell located in the tail-flick analgesia meter (Ugo Basile Tail-flick Unit 7360, Ugo Basile, 
Comerio, Italy) immediately below the tail. The reaction time is automatically recorded. Prior to 
treatment with drugs, the nociceptive threshold was measured three times, and the mean of the 
reaction time was used as the pre-drug latency for each mouse. A cut-off time of 10 sec was used to 
prevent tissue damage. 
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 Hot-plate test 
 
Animals were placed on an electrically heated plate at 55 ± 0.2ºC, and the latency period until 
nociceptive responses such as licking, shaking the legs, or jumping was measured. Prior to treatment 
with drugs, the nociceptive threshold was measured three times, and the mean reaction time was used 
as the pre-drug latency for each mouse. The cut-off time of 30 sec was used to prevent tissue damage. 
Antinociception in tail-flick and hot-plate tests was quantified using the percentage of maximum 
possible effect (% MPE) developed by Harris and Pierson (1964) and calculated as: % MPE = [(test – 
control) / (cut-off time – control)] × 100. 
 
Gastrointestinal transit  
 
Mice were fasted, with water available ad libitum, for 18 h before the experiments. Fifteen 
minutes after s.c. injection of 7-hydroxymitragynine, morphine, vehicle, or saline, a charcoal meal (an 
aqueous suspension of 10% charcoal and 5% gum Arabic) was orally administered at a volume of 
0.25 ml. Thirty minutes after administration of the charcoal meal, the animal was sacrificed by 
cervical dislocation, and the small intestine from the pylorus to the cecum was carefully removed. 
Both the length from the pylorus to the cecum and the farthest distance to which the charcoal meal 
had traveled were measured. For each animal, the percentage of gastrointestinal transit (GIT) was 
calculated as the percentage of distance traveled by the charcoal meal relative to the total length of the 
small intestine. The inhibition of gastrointestinal transit (%) was calculated as: Inhibition of 
gastrointestinal transit (%) = [(saline or vehicle GIT – drug GIT) / (saline or vehicle GIT)] × 100. 
 
Development of tolerance 
 
Morphine or 7-hydroxymitragynine tolerance was produced by twice daily injection of morphine 
(8 mg/kg, s.c.) or 7-hydroxymitragynine (2 mg/kg, s.c.) for 5 consecutive days. The effect of an 
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agonist was measured daily 15 and 30 min after the first administration of 7-hydroxymitragynine and 
morphine, respectively. The development of tolerance was defined as a significant reduction of the 
analgesic effect of the agonist compared with the effect produced by the treatment of the first day.  
 
Determination of cross-tolerance 
 
Animals were pretreated with morphine (8 mg/kg, s.c.), 7-hydroxymitragynine (2 mg/kg, s.c.), 
saline or vehicle by administration twice per day for the first 5 days. On day 6, animals tolerant to 
morphine or non-tolerant (i.e., treated with saline for 5 days) received 7-hydroxymitragynine (2 
mg/kg, s.c.), and the antinociceptive effects were evaluated 15 min later by the tail-flick test. Animals 
tolerant to 7-hydroxymitragynine or non-tolerant (i.e., treated with vehicle for 5 days) received 
morphine (8 mg/kg, s.c.), and the antinociceptive effects were evaluated 30 min later by the tail-flick 
test. 
 
Naloxone-induced withdrawal symptoms 
 
Morphine or 7-hydroxymitragynine was injected s.c. daily at 9:00 AM and 7:00 PM according to 
the schedule reported previously (Suzuki et al., 1995; Kamei et al., 1997; Tsuji et al., 2000). The dose 
of morphine or 7-hydroxymitagynine was progressively increased from 8 to 45 mg/kg over a period of 
5 days. The doses of morphine or 7-hydroxymitragnine (mg/kg) injected at 9:00 AM and 7:00 PM 
were: 1st day (8, 15), 2nd day (20, 25), 3rd day (30, 35), 4th day (40, 45), 5th day (45 at 9:00 AM 
only), respectively. Withdrawal signs were precipitated by injecting naloxone (3 mg/kg, s.c.) 2 hr after 
the final morphine or 7-hydroxymitragnine administration. After the naloxone challenge, mice were 
immediately placed on a circular cylinder (30 cm in diameter × 70 cm height). Naloxone-precipitated 
signs were recorded for 60 min.  
 
Molecular modeling 
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Morphine and 7-hydroxymitragynine were subjected to energy minimization using the 
semiempirical quantum mechanisms method AM1 as implemented in the MOPAC 5.0 programs. The 
superimposed ensemble of morphine/7-hydroxymitragynine was subjected to the overlay program 
implemented in Chem 3D 6.0. 
 
Drugs 
 
The drugs used in this study were morphine hydrochloride (Takeda Chemical Ind., Osaka, Japan), 
naloxone hydrochloride (NX; MP Biomedicals, Irvine, CA), naltrindole hydrochloride (NTI), 
nor-binaltorphimine dihydrochloride (norBNI), naloxonazine dihydrochloride (NLZ), naloxone 
methiodide (NX-M) (Sigma Chemical Co., St. Louis, MO, USA) and β-funaltorexamine 
hydrochloride (β-FNA; Tocris-Cookson, Bristol, UK). Mitragynine was isolated from the extract of 
the leaves of Mitragyna speciosa as described previously (Ponglux et al., 1994), and total synthesis of 
mitragynine was also established (Takayama et al., 1995). 7-Hydroxymitragynine and 
9-hydroxycorynantheidin were synthesized from mitragynine as described previously (Takayama et 
al., 2002). The purity (> 99%) of these compounds was checked by HPLC and 1H-NMR (500 MHz) 
analysis (Takayama et al., 2002). 
For s.c. administration, 7-hydroxymitragynine was dissolved in phosphate-buffered saline (pH, 
5.5). Mitragynine and 9-hydroxycorynantheidine were first dissolved in 100% dimethylsulfoxide and 
then subsequently diluted with 0.5% carboxyl methylcellulose. The final concentration of 
dimethylsulfoxide was 4.8%. Other drugs were dissolved in saline. For p.o. administration, 
7-hydroxymitragynine was dissolved in 10 mM phosphate-buffer (pH, 5.5). Morphine was dissolved 
in distilled water. All the drugs were administered using a volume of 0.1 ml/10 g body weight. 
The opiate antagonists, NX-M (3 mg/kg), NX (2 mg/kg) and NTI (3 mg/kg), norBNI (20 mg/kg), 
and NLZ (35 mg/kg) and β-FNA (40 mg/kg), were administered s.c. 15 min, 30 min, 3 h, and 24 h, 
respectively, before 7-hydroxymitragynine or morphine injection (s.c.).  
 
Statistical analysis 
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 The data are expressed as the mean ± S.E.M. Statistical analyses were performed with two-tailed 
Student’s t-test for comparison of two groups, and by a one-way analysis of variance, followed by a 
Bonferroni multiple comparison test for comparison of more than two groups. A P value < 0.05 was 
considered statistically significant. ED50 values and 95% confidence limits were determined using the 
Litchfield-Wilcoxon method (Litchfield and Wilcoxon, 1949). 
 
 
3. Results 
 
Antinociceptive effect of subcutaneously administered 7-hydroxymitragynine and 
9-hydroxycorynantheidine in mice 
 
7-Hydroxymitragynine (0.25–2 mg/kg, s.c.) induced dose-related antinociceptive responses in 
the tail-flick and hot-plate tests (Figure 2). The effect peaked at 15 and 7.5 min after injection in the 
tail-flick and hot-plate tests, respectively. The ED50 values (95% confidence limits) for 
7-hydroxymitragynine was 0.80 mg/kg (0.48–1.33) and 0.93 mg/kg (0.59–1.45) in the tail-flick and 
the hot-plate tests, respectively. The vehicle did not show any antinociceptive activity in either test. 
Morphine (1.25–8 mg/kg, s.c.) produced dose-related antinociceptive response with a peak effect 
at 30 min in both tests (data not shown). The ED50 values (95% confidence limits) for morphine were 
4.57 mg/kg (3.12–6.69) and 4.08 mg/kg (2.75–6.06) in the tail-flick and hot-plate tests, respectively. 
Compared to morphine on mg/kg (µmol/kg) basis, 7-hydroxymitragynine was 5.7 (6.3) and 4.4 (4.9) 
times more potent in the tail-flick and hot-plate tests, respectively (Figure 6A, B). 
7-Hydroxymitragynine affected behavioral responses: 2 mg/kg of 7-hydroxymitragynine elicited an 
increase spontaneous locomotor activity and Straub tail, as 8 mg/kg of morphine did (data not shown). 
9-Hydroxymitragynine had no measurable antinociceptive effect after s.c. administration at doses 
up to 100 mg/kg (Figure 3A). Mitragynine (60 mg/kg) produced only 30 % MPE value at 60 min after 
s.c. administration (Figure 3B). 
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Figure 1 Chemical structures of mitragynine, 7-hydroxymitragynine, 9-hydroxycorynantheidine, and morphine 
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Figure 2 Time course of the antinociceptive effects produced by s.c. administration of 7-hydroxymitragynine 
(0.25–2.0 mg/kg) in the tail-flick test (A) and hot-plate test (B) in mice. Each value represents mean ± S.E.M. of 
data obtained from seven or eight mice. * P < 0.05; ** P < 0.01, versus the vehicle group. 
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Figure 3 Time course of the antinociceptive effects produced by s.c. administration of (A) 
9-hydroxycorynantheidine (10, 100 mg/kg) and (B) mitragynine (30, 60 mg/kg) in the tail-flick test in mice. 
Each value represents mean ± S.E.M. of six mice. ** P < 0.01, versus the vehicle group. 
 
 
Characterization of the antinociception induced by subcutaneously administered 
7-hydroxymitragynine in mice 
 
In order to determine the opioid receptor type selectivity of 7-hydroxymitragynine 
antinociception, mice were pretreated with selective opioid receptor antagonists (Figure 4). In the 
tail-flick test, the antinociceptive effect of 7-hydroxymitragynine was significantly blocked by the 
non-selective opioid antagonist naloxone, the irreversible µ1/µ2-opioid receptor selective antagonist 
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β-FNA, and the µ1-opioid receptor selective antagonist NLZ. The selective δ-antagonist NTI and the 
selective κ-antagonist norBNI were ineffective against 7-hydroxymitragynine-induced antinociception. 
In the hot-plate test, the effect of 7-hydroxymitragynine was completely blocked by naloxone and 
β-FNA, and partially (38%) blocked by NTI. The κ-opioid receptor antagonist norBNI was ineffective 
against 7-hydroxymitragynine-induced antinociception. When these opioid antagonists were 
administered s.c. alone at the doses used in the present study, they did not produce any changes in the 
tail-flick and the hot-plate test results (data not shown). 
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Figure 4 Effects of opioid receptor antagonists on the antinociception by 7-hydroxymitragynine (2 mg/kg) after 
s.c. administration. The antinociceptive effect of 7-hydroxymitragynine was determined in the mice tail-flick 
test (A) and the hot-plate test (B) after s.c. administration of the following antagonists: naloxone (NX; 2 mg/kg), 
β-funaltrexamine (β-FNA; 40 mg/kg), naloxonazine (NLZ; 35 mg/kg), naltrindole (NTI; 3 mg/kg), and 
nor-binaltorphimine (norBNI; 20 mg/kg). Measurements were performed 15 and 7.5 min after s.c. 
administration of 7-hydroxymitragynine in the tail-flick and hot-plate tests, respectively. Each value represents 
mean ± S.E.M. of seven or eight mice. The asterisk (*) donates values that were significantly different from 
7-hydroxymitragynine treated mice by a Bonferroni test (**, P < 0.01). 
 
 
Effect of 7-hydroxymitragynine on gastrointestinal transit 
   
The effect of 7-hydroxymitragynine on the passage of a charcoal meal was examined. 
7-Hydroxymintragynine (0.25–4 mg/kg, s.c.) and morphine (0.5–8 mg/kg, s.c.) dose-dependently and 
significantly inhibited gastrointestinal transit (Figure 5A, C). The ED50 values (95% confidence 
limits) for 7-hydroxymitragynine and morphine were 1.19 mg/kg (0.54–2.63) and 1.07 mg/kg 
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(0.40–2.86), respectively (Table 1).  
The inhibitory effects of 7-hydroxymitragynine and morphine on gastrointestinal transit were 
similar, and were significantly antagonized by pretreatment with the µ1/µ2-opioid receptor selective 
antagonist β-FNA (40 mg/kg). The µ1-opioid receptor antagonist NLZ (35 mg/kg) slightly blocked the 
effects of 7-hydroxymitragynine and morphine. The peripheral opioid receptor antagonist naloxone 
methiodide (NX-M) slightly blocked the effect of 7-hydroxymitragynine and significantly blocked the 
effect of morphine (Figure 5B, D). No change in the gastrointestinal transit was observed when each 
antagonist was administered alone (data not shown). 
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Figure 5 Effects of 7-hydroxymitragynine and morphine on gastrointestinal transit of a charcoal meal in mice. 
Each drug was administered s.c. 15 min before oral administration of charcoal meal. Gastrointestinal transit was 
determined at 30 min after administration of the charcoal meal. Inhibition of gastrointestinal transit by 
7-hydroxymitragynine (A) and morphine (C). Antagonism of the antitransit effect of a single dose (2 mg/kg, 
s.c.) of 7-hydroxymitragynine (B) and morphine (D) by the following antagonists: β-funaltrexamine (β-FNA; 40 
mg/kg), naloxonazine (NLZ; 35 mg/kg), and naloxone methiodide (NX-M; 3 mg/kg). Each value represents 
mean ± S.E.M. of six or seven mice. The asterisk (*) donates values that were significantly different from 
saline- or vehicle-treated mice by a Bonferroni test (**, P < 0.01). The # donates values that were significantly 
different from agonist alone treated mice by Bonferroni test (#, P < 0.05, ##, P < 0.01). 
  
Table 1 Antinociceptive and inhibitory effects on gastrointestinal transit (IGIT) of morphine and 
7-hydroxymitragynine in mice 
Compound    Tail-flick (TF)   Hot-plate (HP)     IGIT     TF/IGIT   HP/IGIT 
ED50     ED50       ED50
Morphine    4.57 (3.12–6.69)   4.08 (2.75–6.06)   1.07 (0.40–2.86)  4.27     3.81 
7-Hydroxymitragynine  0.80 (0.48–1.33)   0.93 (0.59–1.45)   1.19 (0.54–2.63)  0.67     0.78 
ED50 value represent effective dose (mg/kg) 50% (95% confidence limits).  
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Figure 6 Dose-response curves of antinociceptive effect and inhibitory effect on gastrointestinal transit of 
subcutaneous administration of morphine and 7-hydroxymitragynine in (A) tail-flick test, (B) hot-plate test, and 
(C) gastrointestinal transit. 
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Development of tolerance and cross tolerance following repeated s.c. administration of 
7-hydroxymitragynine or morphine 
 
Antinociceptive effects in mice treated for 5 days with repeated administration of 
7-hydroxymitragynine (2 mg/kg, s.c., twice daily) or morphine (8 mg/kg, s.c., twice daily), are shown 
in Figure 7. The repeated administration of morphine and 7-hydroxymitagynine produced a 
development of tolerance. The animals pretreated with 7-hydroxymitragynine (2 mg/kg, s.c., twice 
daily for 5 days) exhibited significant and complete tolerance to the antinociceptive effects induced by 
7-hydroxymitragynine (Figure 7), and showed cross-tolerance to morphine (Figure 8). Vehicle did not 
affect the antinociceptive responses. As was seen in the 7-hydroxymitragynine-pretreated group, the 
animals pretreated with morphine (8 mg/kg, s.c., twice daily for 5 days) showed cross-tolerance to 
7-hydroxymitragynine.  
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Figure 7 Development of tolerance to the antinociceptive activities of morphine (8 mg/kg, s.c.) and 
7-hydroxymitragynine (2 mg/kg, s.c.) administered twice daily in mouse tail-flick test. Each point represents the 
mean ± S.E.M. of seven or eight mice. ## P < 0.01, versus the antinociceptive activities on the first day of 
7-hydroxymitragynine administration. ** P < 0.01 versus the antinociceptive activities on the first day of 
morphine. 
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Figure 8 Cross-tolerance between morphine and 7-hydroxymitragynine. Groups of seven or eight mice received 
vehicle, 7-hydroxymitragynine (2 mg/kg, s.c.), saline or morphine (8 mg/kg, s.c.) twice daily for 5 days. On day 
six, morphine (8 mg/kg, s.c., open column) or 7-hydroxymitragynine (2 mg/kg, s.c., solid column) was 
administered to each mice. Each column represents the mean ± S.E.M. of eight mice. ## P < 0.01 versus the 
vehicle-treated group. ** P < 0.01, versus the saline-treated group.  
 
 
Naloxone-induced withdrawal signs following chronic treatment of 7-hydroxymitragynine or 
morphine 
 
Morphine-dependent mice, which were treated chronically with morphine, showed withdrawal 
signs such as jumping, rearing, urination, ptosis, forepaw tremor and diarrhea after naloxone (3 mg/kg, 
s.c.) was administered. 7-Hydroxymitragynine-dependent mice, which were chronically treated with 
7-hydroxymitragynine, also showed fewer but significant withdrawal signs after naloxone injection (3 
mg/kg, s.c.), compared with the group of morphine-dependent mice (Table 2). 
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Table 2 Naloxone-precipitated withdrawal responses in morphine- and 7-hydroxymitragynine-dependent mice 
         Positive mice / total mice 
Withdrawal signs         Vehicle        Morphine      7-Hydroxymitragynine 
Jumping     0 / 7    6 / 8    5 / 7 
Rearing     0 / 7    8 / 8    4 / 7 
Urination     0 / 7    8 / 8    6 / 7 
Ptosis     0 / 7    5 / 8    2 / 7 
Forepaw tremor    3 / 7    6 / 8    5 / 7 
Diarrhea     0 / 7    3 / 8    1 / 7 
Each value represents the number of positive animals / the total numbers of total animals. Test drugs were injected 30 min 
before naloxone administration (3 mg/kg, s.c.). 
 
 
Antinociceptive effect of orally administered 7-hydroxymitragynine in mice 
 
7-Hydroxymitragynine (1–8 mg/kg, p.o.) induced dose-related antinociceptive response in the 
tail-flick and the hot-plate tests (Figure 9). The effect peaked at 15 and 7.5–15 min after injection in 
the tail-flick and the hot-plate tests, respectively. The ED50 values (95% confidence limits) for 
7-hydroxymitragynine was 4.43 mg/kg (1.57–6.93) and 2.23 mg/kg (1.38–3.60) in the tail-flick and 
the hot-plate test, respectively. Vehicle did not show any antinociceptive activity in the both tests. 
Morphine (25–100 mg/kg, p.o.) produced dose-related antinociceptive response with a peak 
effect at 60 and 30 min after injection in the tail-flick and the hot-plate tests, respectively. (data not 
shown). The ED50 values (95% confidence limits) for morphine was 63.0 mg/kg (37.2–106.8) and 
48.2 mg/kg (27.5–84.5) in the tail-flick and the hot-plate test, respectively. Compared to morphine on 
mg/kg (µmol/kg) base, 7-hydroxymitragynine was 14.2 (15.7) and 21.6 (23.9) times more potent in 
the tail-flick and hot-plate test, respectively (Table 3 and Figure 10A, B). 
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Figure 9 Time course of the antinociceptive effects produced by oral administration of 7-hydroxymitragynine 
(1–8 mg/kg) in the tail-flick test (A) and hot-plate test (B) in mice. Each value represents mean ± S.E.M. of 
seven or eight mice. * P < 0.05; ** P < 0.01, versus the vehicle group. 
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Figure 10 Antinociceptive potency of morphine and 7-hydroxymitragynine in mice. Dose-response curves of 
morphine and 7-hydroxymitragynine after oral administration: (A) tail-flick test, (B) hot-plate test.  
 
 
 
Table 3 Antinociceptive effect (ED50) of morphine and 7-hydroxymitragynine after s.c. or p.o. administration in 
mice tail-flick and hot-plate tests 
Compound      Tail-flick      Hot-plate   
ED50 (s.c.) ED50 (p.o.)   p.o./s.c.       ED50 (s.c.)    ED50 (p.o.)  p.o./s.c. 
Morphine     4.57     63.0       13.8    4.08     48.2      11.8 
7-Hydroxymitragynine   0.80   4.43      5.54     0.93      2.23         2.40 
ED50 value represent effective dose (mg/kg) 50%.  
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Computational superposition of morphine and 7-hydroxymitragynine 
 
We explored the structural similarity between morphine and 7-hydroxymitragynine using 
molecular modeling techniques (Figure 11). At the outset, we examined the respective 
superimpositions of the nitrogen atom, benzene ring and oxygen function on the benzene ring in 
morphine and 7-hydroxymitragynine. Not all functional groups of the two molecules were 
superimposed. 
 
 
 
 
 
 
 
 
 
 
Figure 11 Overlay of the low-energy conformation of 7-hydroxymitragynine (yellow) and morphine (gray). 
Hydrogen atoms are omitted. Red and blue balls represent oxygen and nitrogen atoms, respectively. 
 
 
4. Discussion  
 
Antinociceptive effect of subcutaneously administered 7-hydroxymitragynine in mice and involvement 
of opioid receptors 
 
To evaluate the antinociceptive effect of the 7-hydroxymitragynine, acute thermal pain (tail-flick 
and hot-plate) tests were performed. The tail-flick test was used to study possible involvement of 
spinal opioid receptors, whereas the hot-plate test was used to study possible involvement of 
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supraspinal receptors. 7-Hydroxymitragynine produced potent dose-dependent antinociceptive effects 
about 5.7 and 4.4 times more potent than morphine in the tail-flick and hot-plate tests, respectively. 
The antonociceptive effect of 7-hydroxymitragynine in the tail-flick and hot-plate tests peaked at 15 
and 7.5 min, respectively, after s.c. administration, while the effect of morphine peaked at 30 min after 
administration in both tests. The higher potency and rapider effect of 7-hydroxymitragynine than 
morphine, may be a result of its high lipophilicity, and its ease in penetrating the blood-brain barrier. 
Indeed, it has been shown that analgesics with high lipophilicity, such as fentanyl, rapidly penetrate 
the blood-brain barrier, and thus fentanyl produces more potent and rapid antinociception than 
morphine does (Narita et al., 2002). In contrast, 9-hydroxymitragynine showed no measurable 
antinociceptive effect after s.c. administration at high doses (100 mg/kg). This may be due to the 
antagonistic effect of 9-hydroxymitragynine. In guinea-pig ileum, 9-hydroxycorynantheidine showed 
antagonistic effect to the µ-opioid agonistic effect of DAMGO (Matsumoto et al., 2006).  
Selective antagonists were employed in order to clarify the involvement of the opioid receptor 
subtypes in the antinociceptive effect of 7-hydroxymitragynine. µ-Opioid receptors are divided into 
two distinct subtypes that mediate antinociception at the spinal and supraspinal levels: the µ1-opioid 
receptor being important for supraspinal antinociception, whereas µ2-opioid receptor is involved in 
spinal antinociception (Ling and Pasternak, 1983; Bodnar et al., 1988; Paul et al., 1989). To 
investigate the relative involvement of µ1- and µ2-opioid receptors in spinal and supraspinal 
antinociception of 7-hydroxymitragynine, the µ1/µ2-opioid receptor antagonist β-FNA and the 
µ1-opioid antagonist naloxonazine were used. It was found that the antinociceptive effects of 
7-hydroxymitragynine are mediated primarily through the µ-opioid receptors because the µ1/µ2-opioid 
receptor antagonist β-FNA almost completely blocked the effect in the tail-flick and hot-plate tests. In 
addition, naloxonazine has been shown to preferentially block µ1-opioid receptors rather than 
µ2-opioid receptors (Sakurada et al., 1999). Naloxonazine significantly blocked the antinociceptive 
effect of 7-hydroxymitragynine in the tail-flick and hot-plate tests, suggesting that the antinociception 
induced by 7-hydroxymitragynine is highly involved in the µ1-receptors. However, it was also found 
that the effect of 7-hydroxymitragynine was partially blocked by the δ-selective antagonist naltrindole 
in the hot-plate test, suggesting partial involvement of the supraspinal δ-opioid receptors. In addition, 
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Thongpradichote et al. (1988) revealed that mitragynine, which is a main constituent of Mitragyna 
speciosa and has structural similarities to 7-hydroxymitragynine, has an antinociceptive activity 
through the supraspinal µ- and δ-opioid receptors. These results suggest that the supraspinal δ-opioid 
receptors are involved in the antinociceptive effect of 7-hydroxymitragynine. 
 
Evaluation of gastrointestinal transit 
 
Opioids are well known to inhibit gastrointestinal transit. In the case of morphine, the dose 
required for its analgesic effect is much higher than required for its constipating effects. We 
investigated the inhibition of gastrointestinal transit to evaluate the inhibitory effect of 
7-hydroxymitragynine on gastrointestinal transit and its antinociceptive effect in comparison with 
morphine. 7-Hydroxymitragynine inhibited gastrointestinal transit in a dose-dependent manner, as 
morphine did. The ratios of ED50 values for the antinociceptive effect in the tail-flick or hot-plate test 
and inhibitory effect on gastrointestinal transit (IGIT) are shown in Table 1. The IGIT ED50 value of 
7-hydroxymitragynine was larger than that of its antinociceptive ED50. On the other hand, morphine 
significantly inhibited gastrointestinal transit at much smaller doses than its antinociceptive doses. 
The IGIT ED50 of morphine was about 4.3 and 3.8 times lower than those of its tail-flick ED50 and 
hot-plate ED50 values, respectively. These results suggest that 7-hydroxymitragynine induces 
constipation less potently than morphine at the equi-antinociceptive doses. 
It appears that among opioid receptors the µ-opioid receptors play a prominent role in 
morphine-induced constipation (Roy et al., 1998). We investigated the pharmacological properties of 
the 7-hydroxymitragynine on the gastrointestinal transit. The inhibitory effect of 
7-hydorxymitragynine and morphine are markedly blocked by β-FNA, indicating that their effects are 
mediated by µ-opioid receptors. It is well known that the inhibitory effects on the gut after systemic 
administration of morphine are mediated by opioid receptors located at central and peripheral sites 
(Goldberg et al., 1998; Shook et al., 1987). We investigated the effect of 7-hydroxymitragynine using 
centrally and peripherally acting antagonists. The inhibitory effects of 7-hydroxymitragynine and 
morphine were slightly blocked by the centrally acting µ1-antagonist naloxonazine. We also 
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investigated the peripheral component using naloxone methiodide, which has restricted access to the 
central nervous system (Lewanowitsch and Irvine, 2002). Naloxone methiodide slightly blocked the 
effects of 7-hydroxymitragynine, although it moderately and significantly blocked the effects of 
morphine. These results suggest that 7-hydroxymitragynine inhibits gastrointestinal propulsive 
activity through central and peripheral opioid receptors. These findings let us speculate that 
7-hydroxymitragynine interacts less with the peripheral opioid receptors than morphine in the 
inhibition of the gastrointestinal transit.  
 
Evaluation of tolerance and cross-tolerance and physical dependence 
 
Repeated exposure to opioid drugs such as morphine leads to the development of tolerance. The 
study of cross-tolerance is a valuable method to define common mechanisms of opioid activities. In 
this study, the development of tolerance and cross-tolerance to 7-hydroxymitragynine and morphine 
following repeated administration of 7-hydroxymitragynine was compared with the 
morphine-pretreated group. Repeated administration of 7-hydroxymitragynine resulted in the 
development of tolerance to its antinociceptive effect. Animals rendered tolerant to 
7-hydroxymitragynine clearly displayed cross-tolerance to morphine antinociception and vice versa. It 
is well known that morphine tolerance is based mainly on µ-opioid receptors (Pasternak, 2001). 
Furthermore, the antinociceptive effects of both 7-hydroxymitragynine and morphine are induced 
mainly through the activation of µ-opioid receptors in mouse tail-flick tests. Taken together, the 
development of tolerance and antinociceptive effects of morphine and 7-hydroxymitragynine are 
supposed to be mediated through the stimulation of µ-opioid receptors. 
As is generally accepted, the potent and repeated stimulation by µ-opioid receptor agonists leads 
to the development of physical dependence (Cowan et al. 1988; Matthes et al., 1996; Narita et al., 
2001). Physical dependence following chronic treatment with 7-hydroxymitragynine was studied. 
Withdrawal signs were observed after naloxone injection, demonstrating that repeated administration 
of 7-hydroxymitragynine induces physical dependence. As described above, the antinociceptive 
effects of 7-hydroxymitragynine was mainly mediated by µ-opioid receptors in the mouse tail-flick 
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and hot-plate test. Furthermore, the mice rendered tolerant to 7-hydroxymitragynine clearly displayed 
cross-tolerance to morphine antinociception in the tail-flick test. These results possibly show 
similarities between naloxone-precipitated withdrawal in morphine and 7-hydroxymitragynine 
dependent mice.  
 
Antinociceptive effect of orally administered 7-hydroxymitragynine 
 
Natives of Thailand and Malaysia use the leaves of the Mitragyna speciosa in fresh or dried 
forms, and they further prepare syrup by evaporating a solution made from dried leaves. The leaves 
are very effective when taken orally (chewed, or the syrup was drunk after dissolving it in hot water). 
Macko et al. (1972) reported that the oral administration of mitragynine was more effective than its 
subcutaneous administration. This suggested that there may be orally active compounds in Mitragyna 
speciosa. When given subcutaneously, 7-hydroxymitragynine produced antinociceptive effect in mice 
tail-flick and hot-plate tests. Their effects were about 5.7 and 4.4 times more potent than that of 
morphine in the tail-flick and the hot-plate tests, respectively. Thus, we investigated the 
antinociceptive effect of 7-hydroxymitragynine via oral route, due to the traditional usage of 
Mitragyna speciosa and clinical relevance of this route to administration for human patients. 
7-Hydroxymitragynine produced dose-dependent and potent antinociceptive effects in the 
tail-flick and the hot-plate tests. It was about 14.2 and 21.6 times more potent than that of morphine 
after p.o. administration in the tail-flick and the hot-plate tests, respectively. Interestingly, 
7-hydroxymitragynine had a favorable bioavailability (oral / subcutaneous dose ratio). Ratios of p.o. 
to s.c. potencies of 7-hydroxymitragynine in the tail-flick and the hot-plate tests were 5.54 and 2.20, 
respectively. On the other hand, ratios of morphine in the tail-flick and hot-plate tests were 13.8 and 
11.8, respectively. These results obtained in this study, suggest that 7-hydroxymitragynine may be a 
therapeutic useful analgesic and support that the traditional use of Mitragyna speciosa per oral 
administration.  
 
Structural similarity between 7-hydroxymitragynine and morphine 
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 Next, we investigated structural similarities between morphine and 7-hydroxymitragynine using 
molecular modeling techniques. As shown in Figure 11, we cannot superimpose all three functional 
groups, i.e., a nitrogen atom, a benzene residue and an oxygen function on the benzene ring in the 
structures of morphine and 7-hydroxymitragynine. These functional groups play a significant role in 
producing analgesic activity (Dhawan et al., 1996). Therefore, it is speculated that 
7-hydroxymitragynine binds opioid receptor sites other than those morphine does. 
 
 
Summary 
 
7-Hydroxymitragynine acts predominantly on µ-opioid receptors, especially on central µ-opioid 
receptors, leading to antinociception. Antinociceptive effect of subcutaneously administered 
7-hydroxymitragynine was about 4–6 times more potent than that of morphine. Especially in oral 
administration, 7-hydroxymitragynine showed 14–22 times more potent. Antinociceptive tolerance to 
7-hydroxymitragynine was developed as was seen with morphine. Cross-tolerance to morphine was 
induced in mice rendered tolerant to 7-hydroxymitragynine and vice versa. On the gastrointestinal 
transit study, 7-hydroxymitragynine was less constipating than morphine at the equi-antinociceptive 
doses. Taken together, 7-hydoxymitragynine has promising characteristic as a novel analgesic because 
of its unique structure and strong potency. 
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Part IV. Effects of mitragynine on isolated tissues 
 
1. Introduction 
 
From the leaves of Mitragyna speciosa, mitragynine was obtained as the major constituent. We 
have studied the pharmacological effects of mitragynine on electrically induced contraction in the 
guinea-pig ileum and radioligand binding assay, and found that mitragynine acts on opioid receptors 
(Watanabe et al., 1997; Yamamoto et al., 1999; Takayama et al., 2002). It was expected that 
mitragynine would exhibit opioid effects in the mouse vas deferens, since opioid receptors are also 
present in this tissue. But in fact, the inhibitory effect of mitragynine on neurogenic contraction of the 
mouse vas deferens was not influenced by naloxone, and its inhibitory effect can not be explained 
only by its opioid effect. It seems that other mechanisms besides stimulation of opioid receptors are 
involved in mitragynine action in its smooth muscle.  
In the present chapter, we investigated the effects of mitragynine on neurogenic contraction in 
various smooth muscle preparations (guinea-pig ileum, mouse vas deferens and guinea-pig vas 
deferens). Neuronal Ca2+ channels play an essential role in neurogenic contraction of the vas deferens. 
Therefore, we investigated the effect of mitragynine on the cytosolic Ca2+ level in cultured 
neuroblastoma cells.  
 
 
2. Materials and methods  
 
Animals 
 
All experiments were performed in compliance with the “Guiding Principles for the Care and 
Use of Laboratory Animals” approved by the Japanese Pharmacological Society. The number of 
animals used was kept to the minimum necessary for a meaningful interpretation of the data, and 
animal discomfort was kept to the minimum. Male albino guinea pigs (320−540 g, Takasugi Lab. 
Animals, Japan) and male ddY mice (25−40 g, SLC, Japan) were killed by CO2 inhalation. 
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 Isolation of guinea-pig ileum 
 
The guinea-pig ileum was dissected and placed in Krebs-Henseleit solution (mM): NaCl, 112.08; 
KCl, 5.90; CaCl2, 1.97; MgCl2, 1.18; NaH2PO4, 1.22; NaHCO3, 25.00 and glucose, 11.49. The ileum 
was placed under 1 g tension in a 5 ml organ bath containing the nutrient solution. The bath was 
maintained at 37ºC and continuously bubbled with a mixture of 95% O2 and 5% CO2. Tissues were 
stimulated by a platinum needle-ring (the ring was placed 20 mm above the base of a needle 5 mm in 
length) electrode. After 60 min equilibration in Krebs-Henseleit solution, the ileum was transmurally 
stimulated (Cox and Weinstock, 1966) with monophasic pulses (0.2 Hz and 0.1 ms duration) by a 
stimulator (SEN-7203, Nihon Kohden, Tokyo, Japan). Contractions were isotonically recorded by 
using a displacement transducer (NEC Type 45347, San-ei Instruments Ltd., Tokyo, Japan). The 
effects of drug treatments on the twitch contractions evoked by transmural stimulation elicited 
through the ring electrodes were examined. At the start of each experiment, a maximum response to 
acetylcholine (3 µM) in each tissue was obtained to check its stability. The mean amplitude of the 
electrically stimulated contraction was about 30% of the maximal response to acetylcholine (3 µM). 
The height of the twitch response to transmural stimulation was measured before and after the drug 
challenge. Contraction (%) is expressed as a percentage of the twitch response to the transmural 
stimulation before the drug challenge. 
 
Isolation of mouse vas deferens 
 
The mouse vas deferens was dissected and placed in eliminating MgCl2 from Krebs-Henseleit 
solution. The tissues were placed under 0.2 g tension in a 5 ml organ bath containing the nutrient 
solution. The bath was maintained at 37ºC and continuously bubbled with a mixture of 95% O2 and 
5% CO2. Tissues were stimulated by a platinum needle-ring (the ring was placed 20 mm above the 
base of a needle 5 mm in length) electrode. After 60 min equilibration in Krebs-Henseleit solution, the 
tissues were transmurally stimulated with a train of 10 pulses, 1.5 msec duration by a stimulator 
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(SEN-7203, Nihon Kohden, Tokyo, Japan) every 30 sec. Contractions were isotonically recorded by 
using a displacement transducer (NEC Type 45347, San-ei Instruments Ltd., Tokyo, Japan). The 
effects of drug treatments on the twitch contractions evoked by transmural stimulation elicited 
through the ring electrodes were examined. The height of the twitch response to transmural 
stimulation was measured before and after the drug challenge. Contraction (%) is expressed as a 
percentage of the twitch response to the transmural stimulation before the drug challenge.  
 
Isolation of guinea-pig vas deferens 
 
The epidydimal portion of the vas deferens was dissected from guinea pigs, and placed in 
Krebs-Henseleit solution of the following composition (mM): NaCl, 112; KCl, 5.9; CaCl2, 2; 
NaH2PO4, 1.2; MgSO4, 1.2; NaHCO3, 25 and glucose, 11; EDTA, 0.03 (pH 7.4). A segment of the vas 
deferens(10−15 mm long) was placed in a 5-ml organ bath containing the nutrient solution and 
suspended from an isometric transducer (Toyo Boldwin, T-7-8-240, Orientec, Japan) under a load of 
0.5 g. Contractions of the preparation were amplified by DC strain amplifier (San-ei 6M92) and 
recorded on a pen-writing recorder (Hitachi, Mod 056). The nutrient solution was maintained at 37˚C 
and saturated with 95% O2 and 5% CO2. Tissues were transmurally stimulated by a needle-ring 
platinum electrode. The needle electrode was vertically positioned and inserted in the lower end, and 
the ring electrode was positioned at the upper end of the preparation. Square-wave pulses (10 Hz, 0.3 
msec duration, 50 V) were delivered to the guinea-pig vas deferens every 1 min for 10 sec. During 
electrical stimulation, mitragynine was cumulatively administered to the bath fluid. The height of the 
twitch response to transmural stimulation was measured before and after the drug challenge. 
Contraction (%) is expressed as a percentage of the twitch response to the transmural stimulation 
before the drug challenge. 
 
Neuroblastoma cell culture 
 
Mouse neuroblastoma cells (N1E-115) were cultured in Dulbecco's modified Eagle's medium 
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(GIBCO, Grand Island, NY, USA) containing 10% fetal bovine serum at 37˚C in a humidified 
atmosphere of 5% CO2 in air. After mechanical agitation, 3 × 104 cells were removed to 35 mm tissue 
culture dishes containing 4 ml of the medium.  After cell attachment, the dish was mounted on the 
stage of an inverted phase-contrast microscope (Nikon, Tokyo, Japan). These cells expressed 
predominately T channel currents (Pang et al., 1990). In experiments where L channels were 
specifically sought, the cells were grown and maintained at confluence for 3–4 weeks under the same 
culture conditions with the addition of 2% dimethylsulfoxide. These cells expressed predominately 
long-lasting (L)-channel currents (Pang et al., 1990). The transient (T)-channel component was very 
small, and, hence, the inward current measured was conducted predominately via L channels at a 
holding potential of –40 mV. 
 
Ca2+ channel current recording in neuroblastoma cells 
 
The whole-cell variation of the patch-clamp technique was used as described previously (Pang et 
al., 1990). The pipettes had a resistance of 2–15 MΩ. Membrane current recordings were made with 
an Axopatch-1B patch-clamp amplifier (Axon Instruments, Union City, CA, USA). All signals were 
filtered at 1 kHz and stored on diskettes by using a digital oscilloscope and its associated disk drive. 
Because the peak currents measured with 20 mM Ba2+ as the charge carrier were usually small (≈ 200 
pA) and the series resistance was usually < 10 MΩ, the voltage error was < 2 mV. Hence, series 
resistance compensation was not usually employed. If the capacitive transient overlapped with the 
onset of the inward current or if the spatial voltage control was inadequate (i.e., N1E-115 cells with 
long neural outgrowths), the experimental data were rejected. The specified the current-voltage plots 
were constructed by using the peak values (corrected for leakage) from the original records for T-type 
or L-type Ca2+ channel currents. The holding membrane potential was fixed at –80 mV when the 
T-type Ca2+ channels were under investigation, while the holding membrane potential was fixed at 
–40 mV when the L-type Ca2+ channel currents were measured. Ba2+ currents through Ca2+ channels 
were elicited by 200 msec depolarization at intervals of 5 sec. Stable readings were first obtained at 5 
min for every single-cell recording, and then the drugs were added to the bath solution. Experiments 
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were performed at room temperature to prolong cell survival and channel recording time. In the 
present neuroblastoma cells studies, stable recordings could be maintained for an average of 30 min. 
The bath solution contained (mM): Tris, 110; KCl, 5; CsCl, 5; 4-(2-hydroxyethyl)-1-piperazine 
ethanesulfonic acid, 20; glucose, 30; BaCl2, 20 and tetrodotoxin, 0.5 µM. 
 
Cytosolic Ca2+ level ([Ca2+]i) in neuroblastoma cells 
 
[Ca2+]i was measured by using fura-2. Neuroblastoma cells (monolayer) grown on glass 
coverslips were incubated with 2 µM fura-2 acetoxymethyl ester for 1 h in a dark place at room 
temperature and then washed 3 times by using a solution containing (mM) NaCl, 145; KCl, 5; CaCl2, 
1; MgCl2, 1; NaH2PO4, 0.5; 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid, 10, glucose, 10 (pH 
7.4) and maintained the same buffer. The glass coverslip attached with cells was transferred to a 1 ml 
Sykes-Moore chamber on the stage of an inverted microscope (Diaphot-TMD, Nikon, Tokyo, Japan). 
The experiments were performed at room temperature. The cells loaded with fura-2 were excited at 
340 and 380 nm, and the fluorescence of these cells was measured at 510 nm by using a 
fluorospectrometer (Spex, Edison, NJ, USA) coupled to an inverted microscope. The [Ca2+]i signal 
was calibrated as described by Grynkiewicz et al. (1985). 
 
Drugs  
 
The following drugs were used: α,β-methylene ATP, prazosin (Sigma, St. Louis, MO, USA), 
norepinephrine bitartarate (Wako, Osaka, Japan), hexamethonium chloride (Tokyo Kasei, Japan), 
tetrodotoxin (Sankyo, Japan), morphine (Takeda Chemical Industries, Osaka, Japan), fura-2 
acetoxymethyl ester (Molecular Probes, Eugene, OR, USA). Mitragynine was isolated from the 
extract of the leaves of Mitragyna speciosa as described previously (Ponglux et al., 1994), and total 
synthesis of mitragynine was also established (Takayama et al., 1995). The purity (>99%) of 
mitragynine was checked by HPLC and 1H-NMR (500 MHz) analysis (Takayama et al., 2002). 
Mitragynine was first dissolved in 100% dimethylsulfoxide to yield a 1 mM solution, and then 
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subsequently diluted with distilled water. Other drugs were dissolved in distilled water. 
 
Statistical analysis 
 
The data are expressed as the mean ± S.E.M. Statistical analyses were performed with two-tailed 
Student’s t-test for comparison of two groups, and by a one-way analysis of variance, followed by a 
Bonferroni multiple comparison test for comparison of more than two groups. A P value < 0.05 was 
considered statistically significant. 
 
 
3. Results 
 
Effect of mitragynine on electrically induced contraction in the guinea-pig ileum and mouse vas 
deferens 
 
The effects of mitragynine and morphine on contraction evoked by single pulse electrical 
transmural stimulation were studied in the guinea-pig ileum (Figure 1). The mean amplitude of ileum 
contraction evoked by electrical stimulation was about 30% of the maximal response to ACh (3 µM). 
This contraction was abolished by tetrodotoxin (100 nM) and atropine (30 nM). However, 
hexamethonium (100 µM) did not affect the contraction (6 ± 3% inhibition). 
The in vitro biological activities were evaluated using isolated guinea-pig ileum for µ-and 
κ-opioid receptors and mouse vas deferens for δ-opioid receptors. To investigate the involvement of 
the µ- and κ- opioid receptor in the effect of mitragynine, we compared the pA2 values of naloxone in 
the response curves for mitragynine, morphine, DAMGO and U69593 in guinea-pig ileum (Table 1). 
Mitragynine inhibited the electrically stimulated contraction in a concentration-dependent manner as 
did morphine and their pD2 values were 6.92 ± 0.05 and 7.67 ± 0.06. The concentration-response 
curves for mitragynine, morphine, DAMGO and U69593 were shifted to the right in the presence of 
naloxone (data not shown). The slope factors for mitragynine, morphine, DAMGO, and U69593 were 
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not significantly different from unity, suggesting the competitive inhibition. The pA2 values of 
naloxone were 8.77 ± 0.12 for mitragynine, 8.61 ± 0.15 for morphine, 8.77 ± 0.35 for DAMGO, and 
7.50 ± 0.36 for U69593. 
Mitragynine also inhibited the electrically elicited mouse vas deferens contraction in a dose 
dependent manner as did morphine and δ selective agonist DPDPE, and their pD2 values were 4.57 ± 
0.14 for mitragynine, 5.85 ± 0.08 for morphine, and 8.53 ± 0.16 for DPDPE. The 
concentration-response curves for morphine and DPDPE were shifted to the right in the presence of 
naloxone or δ selective antagonist naltrindole (data not shown). On the other hand, the inhibitory 
effect of mitragynine on mouse vas deference was not affected by the above mentioned antagonists, 
even at a high dose of 10 µM (Table 2). 
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Figure 1 Effect of mitragynine on twitch response to electrical stimulation in guinea-pig ileum. Data are 
presented as the mean ± S.E.M. of values obtained from 5-6 guinea pigs. Contraction percentage is calculated by 
regarding the resting and electrically stimulated responses (Cont) as 0% and 100%, respectively. *P < 0.05, **P 
< 0.01, significantly different from the control group. MG: mitragynine 0.1–3 µM; Mor: morphine 0.3 µM; Atr: 
Atropine 30 nM; TTX: tetrodotoxin 100 nM; C6: hexamethonium 100 µM 
 
Table 1 pD2 values for inhibition of electrically stimulated contraction by mitragynine and morphine in 
guinea-pig ileum, and pA2 values of naloxone inhibition of mitragynine and morphine 
       pD2    pA2 (naloxone) Slope 
Mitragynine     6.92 ± 0.05  8.77 ± 0.12  0.93 ± 0.13  
Morphine      7.67 ± 0.06  8.61 ± 0.15  1.14 ± 0.20  
DAMGO      7.83 ± 0.07  8.77 ± 0.35  1.18 ± 0.18  
U69593      9.01 ± 0.12  7.50 ± 0.36  1.19 ± 0.09 
pD2 values are the negative logarithm of the IC50 values. The pA2 values are calculated from parallel shifts of the curves for 
the agonists. Data are expressed as the mean ± S.E.M. of five animals. 
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Table 2 pD2 values for inhibition of electrically stimulated contraction by mitragynine, morphine and DPDPE in 
the mouse vas deferens, and pA2 values of naloxone inhibition of mitragynine, morphine and DPDPE 
       pD2    pA2 (naltrindole) pA2 (naloxone) 
Mitragynine     4.57 ± 0.14  < 6    < 6  
Morphine      5.85 ± 0.08  7.74 ± 0.20  8.14 ± 0.15  
DPDPE      8.53 ± 0.16  9.48 ± 0.16  7.19 ± 0.11  
pD2 values are the negative logarithm of the IC50 values. The pA2 values are calculated from parallel shifts of the curves for 
the agonists. Data are expressed as the mean ± S.E.M. of five animals. 
 
Effect of mitragynine on electrically induced contraction in the guinea-pig vas deferens 
 
Figure 2 shows the effect of mitragynine on electrically induced twitch response in the 
guinea-pig vas deferens. Electrical transmural stimulation of the vas deferens elicited twitch 
contractions of smooth muscle. This response was abolished by tetrodotoxin (100 nM), but was not 
inhibited by hexamethonium (100 µM). Prazosin (10 µM) and α,β-methylene ATP (10 µM) decreased 
the twitch response, and the combination of prazosin and α,β-methylene ATP completely inhibited the 
twitch response. Mitragynine (0.3–10 µM) inhibited the twitch response in a concentration-dependent 
manner. The inhibitory effect of mitragynine on electrically-elicited contraction of guinea-pig vas 
deferens was not restored by naloxone (100 µM) (data not shown). Morphine (1 µM) slightly 
inhibited the twitch response.  
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Figure 2 Effect of mitragynine on twitch response to electrical stimulation in guinea-pig vas deferens. Data are 
presented as the mean ± S.E.M. of values obtained from 4-6 guinea pigs. Contraction percentage is calculated by 
regarding the resting and electrically stimulated responses (Cont) as 0% and 100%, respectively. *P < 0.05, **P 
< 0.01, significantly different from the control group. MG: mitragynine 0.3–10 µM; Mor: morphine 1 µM; TTX: 
tetrodotoxin 100 nM; C6: hexamethonium 100 µM; PZ, prazosin 10 µM; MA: α,β-methylene ATP 10 µM. 
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Effect of mitragynine on norepinephrine-, ATP- and KCl-induced contraction in vas deferens 
 
As summarized in Table 3, mitragynine (30 µM) failed to inhibit the contraction by 
norepinephrine or by ATP in guinea-pig vas deferens. In addition, mitragynine (30 µM) did not reduce 
KCl-induced contraction in the presence of tetrodotoxin, prazosin and α,β-methylene ATP. 
Norepinephrine- and ATP-induced contraction was abolished by pretreatment with prazosin and 
α,β-methylene ATP, respectively. 
 
 
Table 3 Effect of mitragynine, prazosin and α,β-methylene ATP (α,β-Me ATP) on contractile response to 
norepinephrine (NE), ATP and KCl in guinea-pig vas deferens  
Compound (Concentration)     Contraction (%) 
       NE (30 µM)  ATP (100 µM)  KCl (50 mM)  
Mitragynine (30 µM)    112 ± 5   133 ± 12   109 ± 3 a
Prazosin (10 µM)    0 b     145 ± 13   − 
α,β-Me ATP (10 µM)    124 ± 7 a   0 b    − 
KCl-induced myogenic contraction was induced in the presence of tetrodotoxin (100 nM), prazosin (10 µM) and 
α,β-methylene ATP (10 µM). Mitragynine, prazosin and α,β-methylene ATP was added to the organ bath 5 min before the 
stimulation. The value of the maximum response to NE or ATP alone, or to KCl with tetrodotoxin, prazosin and 
α,β-methylene ATP was represented as 100%. Data are presented as the mean ± S.E.M. of values determined from 5–6 
guinea pigs. a P < 0.05, b P < 0.01, significantly different from the corresponding control group. 
 
 
Effect of mitragynine on T-type and L-type Ca2+ channel currents in neuroblastoma cells 
 
We recorded two types of Ca2+ channel currents, which were transient (T) or long-lasting (L) 
inward Ba2+ currents. In the normal cells, step depolarization from a holding potential of –80 mV 
evoked transient inward Ba2+ currents. Complete inactivation of these inward currents occurred within 
the 200 msec test pulse.  
Figure 3A shows that mitragynine (1 µM) inhibited the T-type Ca2+ channel currents. The 
currents were activated by depolarizing the cell from a holding potential of –80 mV to –20 mV. 
Records were obtained before and 5 min after the addition of mitragynine (1 µM). The peak inward 
Ba2+ current was measured as the maximum inward current change from the zero current level. 
Mitragynine produced a significant reduction in current amplitude in a concentration-dependent 
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manner (Figure 4A), but did not shift the I-V relationship along the voltage axis (Figure 3A).  
In cells cultured with dimethylsulfoxide, L-type Ca2+ channel currents were most often recorded. 
The holding potential was set at –40 mV, and stepwise depolarization evoked long-lasting inward Ba2+ 
currents. During the 200 msec period of depolarizing pulse, the L-type Ca2+ channel currents were not 
inactivated. Mitragynine inhibited the L-type Ca2+ channel currents (Figure 3B). Figure 4B shows that 
mitragynine inhibited the L-type Ca2+ channel current without altering the channel kinetics. 
 
 
(A) T-type Ca2+ channel currents 
 
 
 
 
 
 
 
 
 
 
(B) L-type Ca2+ channel currents 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Typical recordings showing that effects of mitragynine on (A) T-type and (B) L-type Ca2+ channel 
currents in neuroblastoma cells. (A) Left: original current records at –20 mV. Test pulses of 200 msec were 
applied from a holding potential of –80 mV. The control inward current was determined before application of 
mitragynine. The current was inhibited at 5 min after application of mitragynine (1 µM). Right: curve of the 
current-voltage relationship. Peak current appears at test pulse of –20 mV. (B) Left: Original current records at 
10 mV. Test pulses of 200 msec were applied from a holding potential of –40 mV. Right: curve of the 
current-voltage relationship. Peak current appears at test pulse of 10 mV.○: control; ●: mitragynine 1 µM. 
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Figure 4 Effect of mitragynine on (A) T-type and (B) L-type Ca2+ channel currents in neuroblastoma cells. Data 
are presented as the mean ± S.E.M. of values determined from 4–6 experiments. Peak current (%) is calculated 
by regarding the resting and the stimulated responses (control) as 0% and 100%, respectively. *P < 0.05, **P < 
0.01, significantly different from the corresponding control group (Cont). 
 
 
Effect of mitragynine on KCl-induced cytosolic Ca2+ level ([Ca2+]i) increase in neuroblastoma cells 
 
In the presence of extracellular Ca2+ (1 mM), KCl (15 mM) depolarized the membrane and 
induced a rapid and phasic increase in [Ca2+]i in neuroblastoma cells. After the phasic increase, the 
response to KCl reached a plateau at a level above the basal value. Figure 5A shows the typical 
records of the KCl-induced [Ca2+]i increase before and after exposure to mitragynine (1 µM) and after 
washout of the drug. Mitragynine inhibited the KCl-induced [Ca2+]i increase, and this inhibition was 
abolished by washout. Figure 5B was constructed by using the net increase in [Ca2+]i at the peak 
response. The increase in intracellular Ca2+ by KCl was set to 100%. This inhibitory effect of 
mitragynine is dependent on the concentration used (10 nM–1µM).  
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Figure 5 Effect of mitragynine on KCl-induced [Ca2+]i increase in neuroblastoma cells. (A) Three representative 
records before and after the administration of mitragynine (MG, 1 µM) and washout. The trace shown is a 
typical experiment showing the effect of (a) KCl alone, (b) KCl after incubation with mitragynine and (c) KCl 
after washout. These three tests were performed sequentially on the same cell preparation. ▲: Time when KCl 
(15 mM) was added. (B) Data are presented as the mean ± S.E.M. of values determined from 4–6 experiments. 
The [Ca2+]i increment is expressed as a percentage of the maximum response to KCl in each stimulation. *P < 
0.05, significantly different from the control group. 
 
 
4. Discussion 
 
In the present study, we investigated opioid effects of mitragynine using various isolated tissue 
preparations. The electrically stimulated ileal preparation from guinea-pig was used as a model of the 
action of mitragynine. Mitragynine inhibited the electrically stimulated ileum contraction in a 
concentration-dependent manner as reported previously (Watanabe et al., 1997). The guinea-pig ileum 
contains populations of functional µ- and κ-opioid receptors (Lord et al., 1977; Chavkin and Goldstein, 
1981). The inhibitory effect of mitragynine was antagonized by the opioid receptor antagonist 
naloxone. The pA2 values of the opioid antagonist naloxone against the inhibitory action of µ 
selective agonist DAMGO and κ selective agonist U69593 represent the affinity of naloxone for µ- 
and κ-opioid receptors, respectively. The pA2 value of naloxone against mitragynine was very similar 
to that against DAMGO and morphine but clearly different from that against U69593. It is well 
known that morphine inhibited the guinea-pig ileum contraction predominantly through µ-opioid 
receptors. These results suggested that µ-opioid receptors are involved in the action mitragynine on 
guinea-pig ileum. 
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 In mouse vas deferens, mitragynine inhibited twitch contraction, but its effect was much smaller 
than that of morphine and δ-receptor selective agonist DPDPE. In contrast to morphine and DPDPE 
which were sensitive to naloxone and naltrindole, inhibitory effect of mitragynine was refractory to 
micromolar doses of naloxone or naltrindole. It was expected that inhibitory effect of mitragynine 
may be sensitive to naloxone in the mouse vas deference, since µ-receptors as well as δ- and 
κ-receptors are also present in this tissue, but in fact, the mitragynine effect was not influenced by 
either naloxone or naltrindole, even at high doses. It seems that other mechanisms besides opioid 
receptors are involved in mitragynine action in its smooth muscle.  
Next, we investigated the effects of mitragynine using guinea-pig vas deferens. It is reported that 
the smooth muscle contraction produced by electrical transmural stimulation in guinea-pig vas 
deferens results from norepinephrine and ATP released from nerve endings by excitation of the 
sympathetic neurones (Sneddon et al., 1982). The present study supported these findings: The twitch 
contraction of vas deferens was abolished by tetrodotoxin, but was not affected by hexamethonium. 
An α1-adrenoceptor antagonist, prazosin, or desensitization of the ATP receptor by α,β-methylene ATP 
partly reduced the contractile response. The combined treatment resulted in the complete inhibition of 
electrically induced contraction. Thus, the electrically-induced contraction is due to the excitation of 
postganglionic sympathetic neurones, leading to co-release of norepinephrine and ATP from the nerve 
terminal. Opioid receptors are known to be located in the vas deferens (Traynor, 1994), but morphine 
failed to inhibit the electrically induced contraction in the guinea-pig vas deference. In addition, the 
inhibitory effect of mitragynine was not reversed by naloxone. These results suggest that opioid 
receptors are not involved in its inhibitory effect of this tissue.  
In this tissue, mitragynine almost abolished the electrically induced contraction of the vas 
deferens but failed to affect the responses to norepinephrine or to ATP. Additionally, it did not affect 
KCl-induced contraction in the presence of tetrodotoxin, prazosin and α,β-methylene ATP. This 
KCl-induced contraction results from the excitation of smooth muscle because the neurogenic factors 
elicited by KCl were eliminated under the present condition. Consequently, the effects of mitragynine 
on the receptors and the contractile mechanism of the vas deferens smooth muscle can be negligible at 
a concentration less than 30 µM. Taken together, mitragynine acts not on the smooth muscle, but 
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mainly on the sympathetic nerve, leading to inhibition of the neurogenic contraction of the vas 
deferens. Thus, mitragynine is thought to inhibit neurotransmitter release elicited by nerve 
stimulation. 
Neuronal Ca2+ channels play an essential role in neurogenic contraction of the vas deferens. We 
noted the effect of mitragynine on neuronal Ca2+ channels in N1E-115 neuroblastoma cells. By using 
the patch clamp technique, mitragynine was found to block T- and L-type Ca2+ channel currents in 
neuroblastoma cells. Mitragynine reduced the amplitude of both T- and L-type Ca2+ channel currents 
without altering the channel kinetics. The inhibitory effect was reversible by washout. This is direct 
evidence that mitragynine blocks Ca2+ channels in neuronal cells. Additional evidence for the effect of 
mitragynine on Ca2+ channels is provided by the experiments where [Ca2+]i was measured with the 
fluorescent dye fura-2 in neuroblastoma cells. The cells were stimulated by depolarization with KCl, 
resulting in an increase in intracellular Ca2+. Mitragynine inhibited the increase in [Ca2+]i in response 
to KCl stimulus in neuroblastoma cells. Mitragynine was found to inhibit the electrically stimulated 
contraction of guinea-pig vas deferens, and to block Ca2+ channels in N1E-115 neuroblastoma cells. It 
is speculated that mitragynine inhibits the neurogenic contraction of the vas deferens through the 
blockade of neuronal Ca2+ channels. Some Ca2+ channel blockers have been reported to exhibit 
analgesic properties in some pain tests (Miranda et al., 1993; Chaplan, 2000). It is thought that the 
decrease of neurotransmitters through the blockade of neuronal Ca2+ channels may lead to the 
inhibition of pain transduction. Taken together, the neuronal Ca2+ channel-blocking effect of 
mitragynine may contribute to its analgesic effects. 
 
 
Summary 
 
In the present chapter, mitragynine was found to inhibit the electrically stimulated contraction of 
guinea-pig ileum and vas deferens, and to block Ca2+ channels in N1E-115 neuroblastoma cells. It is 
suggested that mitragynine inhibits the contraction of the guinea-pig ileum and vas deferens through 
the opioid receptors and blockade of neuronal Ca2+ channels, respectively.  
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Concluding Remarks 
 
Mitragyna speciosa has long been used in Thailand, Malaysia, Indonesia, and Papua New 
Guinea for its opium- and coca-like effects. The use of this herb has now been banned in Thailand and 
Malaysia because of its narcotic effect. However, the herb is not under any control in many other 
countries. In this study, I found a novel and potent opioid agonist, 7-hydroxymitragynine, that is a 
minor constituent of Mitragyna speciosa.  
 
Discovery of 7-hydroxymitragynine from Mitragyna speciosa as an opioid agonist 
 
We previously found that the antinociceptive effect of the main constituent, mitragynine, is less 
potent than that of the crude extract of Mitragyna speciosa. This finding suggests that one nor more 
minor constituents of Mitragyna speciosa have a very potent antinociceptive effect. In the present 
study, I studied the opioid agonistic effect of other constituents of Mitragyna speciosa using in vitro 
assays. Among them, 7-hydroxymitragynine showed the most potent opioid effect, which suggested 
that the opioid effect of Mitragyna speciosa is mostly based on the activity of 7-hydroxymitragynine.  
 
Opioid agonistic effects and involvement of µ-opioid receptors on the effect of 7-hydroxymitragynine 
 
7-Hydroxymitragynine showed selectivity for µ-opioid receptors in isolated guinea-pig ileum, 
mouse vas deferens contraction, and receptor-binding assays. 7-Hydroxymitragynine has full agonist 
properties on µ-opioid receptors in vitro. In in vivo assays, 7-hydroxymitragynine was found to be a 
potent µ-opioid antinociceptive compound. 7-Hydroxymitragynine showed potent antinociceptive 
activities when administered subcutaneously. It was about 4–6 fold more potent than that of morphine. 
Interestingly, this alkaloid is effective when administered orally. The effect was 14–22 fold more 
potent than that of morphine when orally administered, and had a favorable bioavailability 
(oral/subcutaneous dose ratio). In addition, it induced a more rapid effect than morphine. These results 
obtained in this study, strongly support the traditional oral administration of Mitragyna speciosa.  
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 Side effects of 7-hydroxymitragynine 
 
Morphine plays an important role as pain relieving agent, but it has a number of side effects, e.g., 
constipation, tolerance, and dependence. I evaluated the side effects of 7-hydoxymitragynine in 
comparison with morphine. Repeated subcutaneous administration of 7-hydroxymitragynine resulted 
in the development of tolerance and cross-tolerance to morphine. Naloxone-induced withdrawal signs 
were elicited equally in mice chronically treated with 7-hydroxymitragynine or morphine. On the 
gastrointestinal transit study, 7-hydroxymitragynine was less constipating than morphine at the 
equi-antinociceptive doses. 
 
Potential utility of 7-hydroxymitragynine as an opioid analgesic 
 
Clinical studies have demonstrated that when opioids are used to control cancer pain, physical 
dependence and analgesic tolerance are not a major concern. Constipation is a major problem during 
morphine administration, however. Therefore, 7-hydroxymitragynine is superior to morphine as an 
analgesic because 7-hydroxymitragynine was less constipating than morphine. 7-Hydroxymitragynine 
is structurally different from clinically used opioid agonists, such as morphine, fentanyl, and 
buprenorphine. It is speculated that the pharmacophore binding of 7-hydroxymitragynine to opioid 
receptors is difference from that of morphine. This may lead to a potential difference between the 
opioid effects of 7-hydroxymitragynine and morphine. Furthermore, the antinociceptive effect of 
7-hydroxymitragynine is more potent than that of morphine, especially when administered orally. 
Therefore, the study of the pharmacological effects of alkaloids derived from 7-hydroxymitragynine is 
useful for the development of novel opioid agonists. Further studies of 7-hydroxymitrgynine and its 
related compounds will address development of novel analgesics for clinical management of pain, like 
the development of analgesics that have morphinan structures. 
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